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Abstract

The role and clinical significance of microorganisms in presumed aseptic revision total
hip (THA) and knee arthroplasty (TKA) is unclear. The primary aim of this thesis was to
determine the prevalence and infection-free survival of presumed aseptic revisions with
unexpected positive intraoperative cultures (UPC) by analyzing the largest cohorts of UPC in the
literature. Secondarily, a prospective pilot study using modern molecular techniques with an
emphasis on stringent control of contamination was designed to determine how frequently
microorganisms are present on implants of presumed aseptic revisions, as well as their location
and association with reason for revision.
The prevalence of UPC was approximately 10%, the infection-free survival is
encouraging, and the infection-free survival from the same UPC microorganism is outstanding.
Patients with 2 UPC or a single UPC treated with antibiotics were more likely to have recurrent
infection caused by the UPC microorganism. Patients with a single UPC and no other signs of
infection do not require antibiotic treatment.
The rate of UPC in the prospective molecular pilot study was also approximately 10%
and we hypothesize that microorganisms will frequently be found on implants of ‘aseptic’
failures and associated with location and reason for revision.

Keywords
Total hip arthroplasty, total knee arthroplasty, revision, revision hip arthroplasty, revision
knee arthroplasty, aseptic, aseptic revision, unexpected positive cultures, microorganisms,
polymerase chain reaction, PCR, periprosthetic infection, prevalence, survival, outcomes
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Lay Summary
Over 1-million total hip (THA) and knee replacements (TKA) are performed in North
America every year. Unfortunately, about 12% of these fail by the 10-year mark and require
revision surgery to treat. Infection is a common reason for failure, however, there is no perfect
test to diagnose infection. This can lead to the problem of unexpected positive bacterial cultures
(UPC) in revisions done for non-infected reasons (loosening, instability, others). This is a
problem because the surgical treatment of infected versus non-infected failure differs greatly.
How often UPC occurs in presumed non-infected revisions is unclear. The optimal treatment and
outcomes for these patients is also unclear.
The first goal of this thesis was to study UPC in the largest group of presumed noninfected revision THA and TKA patients to date. We found that about 10% of presumed ‘noninfected’ revisions have UPC. Most patients with UPCs did well and only a small number
required more surgery for infection-related failure. Patients with a higher number of UPCs and
those that were deemed to require antibiotic treatment were more likely to have infection-related
failure caused by the same UPC bacterial microorganism. Lastly, patients with only one UPC
and no other signs of infection do not require antibiotic treatment.
Furthermore, it is now suspected that a large number of ‘non-infected’ loose or failed
implants are actually undiagnosed infection because modern molecular methods have identified
bacterial microorganisms on some failed implants and a proportion of known infections never
grow a bacterial microorganism.
Therefore, the second goal of this thesis was to design a modern molecular gene
sequencing study to identify how often and what type of bacterial microorganisms are on
THA/TKA implants that required revision surgery for ‘non-infection' causes. We expect to show
that implants are frequently contaminated with bacterial microorganisms, and that bacterial
microorganisms are associated with certain locations of failed joint implants and the reason for
failure. These results will provide an important steppingstone to develop future studies that can
determine the role and significance of microorganisms in presumed ‘non-infected’ THA and
TKA failure, which we think may be greatly underestimated.
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Chapter 1
1.

Introduction and Literature Review

1.1

Total Hip and Total Knee Arthroplasty
Arthritis of the hip and knee are among the most symptomatic and disabling of all

joints(1). Hip and knee arthritis is characterized by pain and stiffness that results in substantial
loss of function and quality of life(2). Total hip arthroplasty (THA) and total knee arthroplasty
(TKA) are the modern treatment for symptomatic, end-stage arthritis of these joints when
conservative measures fail. In this patient population, THA and TKA are highly successful at
relieving pain, restoring function, and improving quality of life(3,4). In fact, total joint
replacement is amongst the most successful and cost-effective treatments in all of medicine, and
THA has been labelled as “the operation of the century”(5).

1.1.1

Indications for Total Hip and Knee Arthroplasty
The most common etiology for both THA and TKA is primary osteoarthritis (OA),

accounting for more than 90-98% of patients(3,4,6). Other less frequent aetiologies include posttraumatic osteoarthritis, inflammatory arthritis, osteonecrosis, fracture, congenital abnormalities
such as development dysplasia, childhood conditions such as a slipped capital femoral epiphysis
or Perthes disease, or sequelae from a remote septic native joint arthritis(3,4,6).
Diagnosis is based on a detailed history, physical examination, x-rays, and occasionally
additional tests such as laboratory studies or advanced imaging modalities. Initial management
for OA, the most common etiology, should be conservative and include patient education,
activity modification, weight loss, targeted physiotherapy, non-narcotic pain medication,
injections, and the use of mobility aids when applicable(7,8).
There are no treatments currently available that can prevent or reverse OA. When hip or
knee arthritis leads to unacceptable pain, loss of function, and reduced quality of life despite
conservative or less invasive surgical treatments, the patient is a candidate for THA/TKA.
Traditional indications were limited to very elderly patients with severe-end stage OA, pain, and
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disability because of concerns of implant longevity. However modern studies have supported the
expansion of these indications to include younger patients and those with less than end-stage OA
or disability(3,4,9).

1.1.2

Epidemiology and Economic Impact of Arthritis
Arthritis is a leading cause of disability globally that causes significant societal burden, as

well as physical and psychological suffering to affected individuals(2,10,11). OA is the leading
cause of physical disability in Canada affecting over 4.6 million people and costing over $33
billion annually in healthcare costs and lost productivity(12,13). The prevalence of hip and knee
OA is projected to increase substantially in North America and globally, in part due to an ageing
population and increasing obesity(11,14). This has important economic implications, with the
economic burden of OA in Canada projected to exceed $405 billion by the year 2020(12).

1.1.3

Epidemiology of Total Hip and Knee Arthroplasty
THA and TKA are very common procedures globally and the demand is increasing

rapidly(3,4). In Canada more than 130,000 hip and knee replacements were performed between
2017 to 2018(6). In the United States of America (USA) approximately 400,000 THA and
700,000 TKA are performed annually(15,16). It has been projected that by the year 2030 in the
USA the demand for THA and TKA will increase by 174% and 673%, respectively(14). Recent
data suggests that the demand for THA and TKA by 2030 will likely exceed these estimates(16).
Meeting this demand has important implications for patients and society. Enhancing access to
THA/TKA would result in an estimated cost savings of over $17 billion to the Canadian
economy by 2040(12). Conversely, failing to meet these demands would result in substantial
physical and psychological disability to patients and cost to society.

1.2 Revision Total Hip and Knee Arthroplasty
Despite advances in implant technology, perioperative care, and surgical technique, THA
and TKA do not always last the patient’s entire life and can require revision surgery to replace
the failed components. A systematic review of national joint registers and clinical studies
demonstrated that revision rates are about 6% at 5 years and 12% at 10 years for both primary
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THA and TKA(17). A recent systematic review and meta-analysis looking of case series, cohort
studies, and registry data with a minimum of 15-year follow-up showed that the approximate 25year survival of TKA is 82%(18). In a separate publication the same authors found that the 25year survivorship of THA is 77.6% from case series and 57.9% from joint replacement
registries(19). However, the introduction of modern highly cross-linked polyethylene acetabular
component liners may improve the survival of THA(20,21). Furthermore, there are long-term
reports of modern uncemented femoral implants with 15-year survival of 99.5% with revision for
aseptic loosening as the end-point(22).

1.2.1

Epidemiology and Outcomes
In Canada from 2017 to 2018 more than 9,700 THA and TKA revision surgeries were

performed, representing 8.2% and 6.9% of all THA and TKA performed(6). Revisions cost
nearly 80% more than primary replacements when considering inpatient costs, amounting to
$163 million during the same time period(6). As the demand for primary THA and TKA
continues to increase, so too does the number of revision surgeries(3,4,6). It is estimated that
between 2005 and 2030, THA and TKA revisions in the USA will increase by 137% and 601%,
respectively(14). In the USA, the mean total charge for revision THA and TKA is $77,851 and
$75,028 respectively, costing the healthcare system well over 1 billion dollars annually(23,24).
There are many documented risk factors for revision of primary THA and TKA. These
include but are not limited to diagnoses other than primary OA as the indication for primary joint
replacement, implant design/material, male sex, younger age, obesity, increased patient medical
comorbidity, excessive alcohol use, active drug use, coagulopathy, mental health disorders, and
low hospital/surgeon volume(25–28).
Although revision surgery can restore function and quality of life, revisions are
associated with increased risk of morbidity, increased costs, lower patient satisfaction, and
reduced patient reported outcomes when compared to primary THA/TKA(29,30).

1.2.2

Etiology for Revision
Canadian registry data from 2017 to 2018 shows that the most common causes for

revision THA are instability, aseptic loosening (AL), and infection, and for revision TKA are AL
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(26.7%), infection (21.2%), and instability (15.8%)(6). The Australian Orthopaedic Association
National Joint Replacement Registry, considered the gold standard for joint registries, showed
similar findings with a revision burden of 8.4% for THA and 8.7% for TKA(21). The most
common reasons for revision THA were infection, AL, dislocation, fracture, and metal reaction.
The most common reasons for revision TKA were infection, loosening, instability, and pain(21).
A 2009 USA database study found that the most common reasons for revision THA were
instability (22.5%), AL (19.7%), and infection (14.8%), followed by implant failure, osteolysis,
and periprosthetic fracture(31). More recent USA data shows that instability and AL remain the
most common reasons for revision THA, followed closely by infection(23). However, infection
has been reported as the most common cause of revision THA failure (30%), followed by
instability (25%) and loosening (19%)(32). Current USA data shows that the most common
cause for revision TKA is infection (20.4%), followed very closely by AL (20.3%)(24). Another
large single center study listed causes for revision TKA in decreasing order as AL, infection,
instability, periprosthetic fracture, and arthrofibrosis(33). When looking at early versus late
failures, the authors found that infection was the most common cause for early revision and AL
was the most common cause for late revision.
In summary, the current evidence shows that infection and AL are the most common
causes for revision of primary THA and TKA, with instability being another leading cause.
Additionally, infection is a leading cause of failure for revision THA and TKA with rates as high
as 30%.

1.3 Periprosthetic Joint Infection in Total Hip and Knee
Arthroplasty
The definition of periprosthetic joint infection (PJI) is an infection involving the
prosthesis of the THA/TKA and the contiguous tissue. Despite considerable efforts, PJI remains
one of the most common causes of revision in primary THA/TKA, and a leading cause of failure
in revision THA/TKA.
Several classification systems have been developed for PJI. The simplest classification
scheme devised is based solely on time from joint replacement to infection. Although
controversy exists regarding the exact time cut-offs, PJI can be classified as early, delayed, or
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late-onset(34). Early-onset PJI occurs less than 3 months from the time of surgery. Early-onset
PJI is often caused by more virulent microorganisms through intraoperative contamination. The
time period of delayed-onset PJI is between 3 and 12-24 months. Delayed-onset PJI is also
thought to originate at the time of surgery but by less virulent organisms, leading to the delayed
onset of symptoms and diagnosis(34). Late-onset PJI occurs after the 12-24 month time period,
and is thought to be caused most commonly by hematogenous infection or at the time of surgery
by extremely low virulent microorganisms(34).
Another popular and commonly used PJI classification scheme categorizes PJI by
presumed mode of infection in addition to time since surgery(35,36). The first category is
patients undergoing presumed aseptic revision surgery with unexpected positive intraoperative
cultures (UPC). This is an area of considerable debate and not all patients with an UPC have a
diagnosis of PJI. The second category is early postoperative infection, defined as occurring
within 1 month from surgery in this classification scheme. PJI that occurs later than 1 month
after the index procedure is classified as late chronic PJI, and like the delayed and late-onset PJI
of the previous classification scheme, is usually characterized by indolent microorganisms and
symptoms. The fourth and final category of PJI is acute hematogenous spread. This classification
system has gained popularity because it can help guide the medical and surgical management of
PJI. Lastly, authors have modified these classification schemes to include the status of the host
patient in terms of comorbidity and immune function(37).
In response to the burden of PJI, leading experts from many subspecialty fields across the
globe met to evaluate the evidence and reach a consensus on the prevention, diagnosis, and
management of PJI. This culminated in the first International Consensus Meeting (ICM) on
Periprosthetic Joint Infection in 2013 and the second ICM on Musculoskeletal Infection in
2018(38,39). Despite these considerable efforts, PJI remains a devastating complication of total
joint replacement surgery and poses an incredible burden on patients, healthcare systems, and
society.

1.3.1

Epidemiology of PJI
The risk of PJI after primary THA or TKA is approximately 2% per year(40–43). Nearly

70-80% of PJI is diagnosed within the first 2 years, however, one-fourth to one-third are
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diagnosed after the 2-year mark(44,45). Despite all efforts toward the prevention and treatment
of PJI, the incidence is not decreasing and may actually be increasing(40–42). Additionally, PJI
remains the leading cause of failure of TKA and amongst the most commons causes for THA.
Since the incidence of PJI is not decreasing, the number of PJI cases are expected to increase
proportionately with the projected increases in the numbers THA and TKA performed(14,16,41).
The economic cost of PJI is enormous. The mean annual cost to treat chronic PJI case in
a tertiary center in the USA was $88,623 for THA and $116,383 for TKA(46,47). The same
authors showed that the cost of treating septic revisions was 3 to 4 times higher compared to
aseptic revisions. Other authors have reported that PJI costs 5 to 6 times that of primary total
joint replacement(48). Similar high costs for the treatment of PJI in THA/TKA are reported in
the literature(40,49). The cost to the USA healthcare system of treating PJI is projected at $1.6
billion by 2020(40). However, this figure is a gross underestimation of the overall costs of PJI
because authors only considered the direct hospital costs, disregarding many other substantial
direct and indirect costs(34). The economic burden of the projected increased numbers of PJI in
the future has the potential to overwhelm healthcare systems worldwide.
The identification of risk factors for PJI in THA/TKA has been an area of great interest.
The goal is to detect high risk patients and develop strategies to prevent PJI by reducing
nonmodifiable risk factors and optimizing modifiable risk factors. Several nonmodifiable and
modifiable patient, surgical, and healthcare risk factors for PJI have been identified. A
prospective, observational cohort study of over 620,000 primary TKA patients with a median
follow-up of 4.6 years identified male sex, younger age, elevated body mass index (BMI),
diabetes, dementia, previous septic arthritis, a diagnosis of fractured femoral neck, the use of
metal versus ceramic bearings, and the surgical approach (controversial) as significant risk
factors for PJI(50). Three recently published reviews on PJI identified male gender, obesity,
increased BMI, low BMI/malnutrition (Albumin <34g/L or total lymphocyte count less than
1200 cells per μL), diabetes, increased hemoglobin A1c, chronic kidney disease, rheumatoid
arthritis, malignancy, immunosuppressive medications (steroids, biologic disease-modifying
antirheumatic drugs, chemotherapy) immunosuppressive disorders (human immunodeficiency
virus/AIDS, Hepatitis C), smoking, nasal Staphylococcus aureus colonization, substance abuse,
prolonged surgical time, post-traumatic arthritis (particularly requiring previous
surgery/hardware), revision joint replacement surgery as compared to primary surgery, previous
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septic arthritis, peri-operative allogeneic blood transfusion, active infection at a distant site, and
prolonged drainage of the surgical wound as risk factors for PJI in THA/TKA(34,43,51).

1.3.2

Pathogenesis
The most common cause of PJI is the introduction of microorganisms to the prosthetic

joint or surrounding periprosthetic tissue during the index surgery(34,52). Approximately twothirds of PJI are originated from this mechanism, as are the vast majority of early PJI and those
during the first year. The contamination of microorganisms during index procedure occurs
through aerosol contamination or direct contact(34). High virulence microorganisms are more
likely to cause early PJI with clear signs of aggressive infection, whereas lower virulence
microorganisms are more likely to cause late or chronic PJI with indolent signs of infection such
as progressive pain or component loosening(51,52).
The second mechanism is contiguous spread of infection from an external or adjacent
site(34,43,51). This could include direct spread of microorganisms from a superficial surgical
site infection in the setting of prolonged drainage, adjacent soft tissue or bone infection
(osteomyelitis), or an injury that exposes the prosthetic implants to the external environment
(open periprosthetic fracture). Lastly, all prosthetic joints are at risk of hematogenous seeding of
microorganisms from a distant primary focus of infection(34,51,53). Although these infections
can occur during any period of life of the prosthesis, acute hematogenous PJI occurs most
commonly in the first year and presents as an aggressive acute PJI after a pain-free interval(53).
Common foci of infection include other prosthetic devices, and skin, oral cavitary, genitourinary,
gastrointestinal, and cardiovascular sources(53). Bacteremia is commonly associated with acute
hematogenous PJI, commonly caused by being Staphylococcus aureus, Streptococci, and
Enterococci (34,53). Other gram-negative microorganisms, coagulase-negative Staphylococci,
and rare microorganisms are encountered as well(34,53).
A major factor in the pathogenesis of PJI in THA/TKA is the presence of biofilms. In the
presence of a foreign body such as a THA/TKA prosthetic implant, the concentration of bacteria
required to induce a infection is decreased by greater than 100,00 times(54). Microorganisms
have developed the basic survival mechanism of adhering to surfaces of foreign bodies and
creating microcolonies by multiplying while encasing themselves within a glycocalyx biofilm to
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resist environmental factors(43,55). The two most common microorganisms involved in PJI,
Staphylococcus aureus and coagulase-negative Staphylococci, are recognized as biofilm forming
microorganisms. It is through the formation of biofilm that normal microbial flora (considered
innocuous) become pathogens in the presence of THA/TKA prostheses(34). Biofilm formation
takes up to 4 weeks to mature and occurs in 4 general stages: attachment, initial growth,
maturation, and detachment(34,55). Microorganisms in the biofilm state are difficult to isolate
and are protected from the host immune system and antimicrobials, hence why surgical
management is often required for eradication(34,55,56). Microorganisms in biofilms are resistant
to antimicrobial agents because of their slow rate of growth, subpopulations of resistant bacteria,
and the biofilm microenvironment that impedes microbial activity(51,57,58). A majority of the
microorganisms in biofilms remain adherent to the surface of prosthesis limiting the sensitivity
of traditional synovial fluid and tissue cultures, particularly in late or chronic PJI(34).
Furthermore, microorganisms in chronic PJI biofilms can remain in dormant states resistant to
traditional culture techniques(34). Thus, the presence of biofilms can impede the diagnosis of PJI
in THA/TKA.

1.3.3

Microbiology and Microorganisms
Nearly all PJI in THA and TKA is caused by bacterial microorganisms. Methicillin-

sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA),
methicillin-resistant Staphylococcus epidermidis (MRSE), and methicillin-sensitive
Staphylococcus epidermidis (MSSE) are the most common PJI microorganisms in the USA(59).
Conversely, in Europe the most common microorganisms in order of descending frequency are
coagulase-negative Staphylococcus species (CNS), Staphylococcus aureus (S. aureus),
Streptococci, and Enterococci(60). The incidence of MRSA infection in THA/TKA is estimated
at 12-23% in the USA, and the increasing incidence of antimicrobial resistant microorganisms is
associated with increased costs of treatment and poorer outcomes(43,49).
A comprehensive and well-written microbiological review of PJI synthesized the findings
of 14 large studies on PJI including over 2400 patients from different geographic locations and
time periods(34). The majority of THA/TKA PJI involve gram-positive cocci, with over 50 to
60% of PJI caused by S. aureus and CNS. In all infections S. aureus and CNS contributed equal
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amounts, however CNS tended to be more common in THA with equal contributions in early and
delayed/late infections, whereas S. aureus was more common in early-onset infections and
TKA(34). S. aureus is also the most common causative microorganism in hematogenous PJI in
the delayed or late time period. The gram-positive Streptococci and Enterococci species
accounted for less than 10% of PJI cases. Streptococcus species PJI most commonly present in
the delayed or late onset time-period and are often presumed to be caused by acute
hematogenous seeding from gastrointestinal, genitourinary, and skin sources(34,61). Patients
with Streptococci species PJI tend to present acutely, are often systemically ill with associated
bacteremia (as many hematogenous PJI are), and can be difficult to treat(62,63). Enterococci
species PJI are rare but contributes to 12-15% of early PJI, can be associated with lower
virulence delayed PJI, and is associated with polymicrobial infections(34,64). Aerobic gramnegative bacilli constitute less than 10% of all PJI (most commonly Escherichia coli &
Pseudomonas aeruginosa), but account for one-quarter of early-onset PJI(34). S. aureus and
gram-negative bacilli account for more than 60% of early infections due to the high virulence
nature of these microorganisms, and tend to present as acute infections(34).
Delayed or late PJI tends to be caused by lower virulence microorganisms such as CNS
(normal human microbiome on skin) or Enterococcus species with an insidious onset of
nonspecific symptoms such as pain and swelling(34,43,51). The most common CNS
microorganism in PJI is Staphylococcus epidermidis (S. epidermidis), a known former of
biofilm(34,43,55). S. epidermidis is the second most common causative microorganism in early
PJI, but also a player in delayed or late PJI due to its low virulence(34,43,55). Another low
virulence microorganism increasingly being recognized as a contributor to late onset PJI is the
anaerobic gram-positive bacilli Cutibacterium acnes (C. acnes), formerly known as
Propionibacterium acnes(34,43,51). C. acnes is part of the normal human microbiome found on
skin and sebaceous glands, has been implicated more in THA versus TKA PJI, and is most
commonly introduced into the joint from contamination during the index surgery(34,65). C.
acnes represents a diagnostic challenge because it is difficult to grow with standard laboratory
techniques (requiring extended anaerobic cultures), presents with indolent symptoms, often does
not induce increased or abnormal standard diagnostic inflammatory markers, and may be
considered a contaminant(43,66).
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Only 15% of PJI in THA/TKA is polymicrobial, however these infections account for
nearly 31% of early onset PJI(67). Anerobic bacterial microorganisms are a less common cause
of PJI, but when present are often associated with polymicrobial infections(67). Mycobacteria
are an extremely rare cause of PJI, but can occur in developing countries(68). Many other
bacterial microorganisms have been associated with PJI, although much less common and
outside of the scope of this review(34,43,51). Less than 1% of PJI are caused by fungal
microorganisms, however fungal infections are more common in multiply revised cases and
Candida species are the causative microorganisms in over 80%(69).
Culture-negative PJI is increasingly recognized and presents multiple diagnostic and
treatment challenges, however, this will be discussed in the next section.

1.3.4

The Diagnosis of PJI in THA and TKA
The diagnosis of PJI is based on a combination of clinical, serum, synovial fluid,

microbiologic culture, histopathology, and intraoperative findings. Despite enormous focus and
scientific efforts, there is no gold standard or perfect test to diagnose PJI.
Early PJI often presents with wound drainage, erythema, swelling, severe pain, and
aggressive clinical signs secondary to the high virulence microorganisms often involved.
Delayed and certainly late-onset PJI often present with indolent local non-specific signs of
infection such as pain, swelling, or implant loosening due to the lower virulence of causative
microorganisms. However, a draining sinus can still occur in the late time period. Additionally, if
secondary to acute hematogenous seeding the patient can present with acute, aggressive local and
systemic signs of infection. Plain radiographs are obtained routinely in the evaluation of any
THA or TKA suspected of PJI, pain, or dysfunction. Radiographic signs of loosening can
suggest an infectious process, but no radiographic signs are sensitive or specific for the diagnosis
of PJI(70).
Screening bloodwork and joint synovial fluid aspiration (when infection is suspected) are
the next diagnostic steps and critical to the evaluation of PJI. Advanced nuclear imaging
modalities have been investigated, however are not routinely used to make the diagnosis of PJI
due to inadequate specificity and increased costs(51,71,72).
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In 2011 a workgroup created by the Musculoskeletal Infection Society (MSIS) analyzed
the best available evidence to produce a landmark consensus statement on the definition of PJI in
THA/TKA(73). Prior to this there was no widely accepted standardized criteria to diagnosis PJI.
This was an enormous step forward in terms of diagnosing PJI and aiding further scientific
research in the area. During the inaugural 2013 ICM of PJI delegates across the globe made a
slight alteration to the minor criteria of the 2011 MSIS definition and published the updated
document(74). This definition of PJI was widely adopted in both clinical and scientific settings.
There are 2 major and 5 minor criteria for the diagnosis of PJI. One of two major criterion is
required (I) 2 positive periprosthetic cultures with the same microorganism or (II) a sinus tract
communicating directly with the prosthetic joint. If major criteria are not met, there are 5 minor
criteria in the 2014 definition, with 3 of 5 required for a diagnosis of PJI(74). Minor criteria are
(i) elevated serum c-reactive protein (CRP) or erythrocyte sedimentation rate (ESR), (ii) elevated
synovial fluid white count (or + + change of leukocyte esterase test strip), (iii) elevated synovial
polymorphonuclear neutrophil (PMN) percentage, (iv) a single positive microorganism culture,
and (v) positive histologic analysis of operative periprosthetic tissue with microscopy. Specific
numeric cut-offs for acute and chronic PJI for these criteria were published(74). The sensitivity
and specificity of these criteria have been validated. Cultures can be obtained preoperatively
from synovial fluid aspiration of the prosthetic joint or intraoperatively at the time of revision
surgery. Ideally, a diagnosis prior to revision surgery is the goal. There has been extensive study
on cultures in the setting of PJI(34,51). Culture isolation of causative microorganisms from
periprosthetic tissue or fluid samples remains the gold standard in diagnosing PJI. Numerous
periprosthetic tissue cultures should be taken intraoperatively to identify the causative
microorganism(75). The practice of sending intraoperative swabs for cultures should be avoided,
as it has been shown that tissue samples are both more sensitive and specific(76). It has also been
shown that interface membrane periprosthetic tissue samples have the highest diagnostic yield
compared to pseudocapsule, other surrounding tissues, or synovial fluid(77,78). Although there
has been little and conflicting study on the subject matter, culturing scrapings from the removed
implants may be more sensitive than tissue cultures(78,79). Additionally, the advent of extended
aerobic and anaerobic cultures (10-14 days) has increased the diagnostic yield of cultures
particularly for low virulence or slow growing organisms(51,80).
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Indirect biomarkers of infection need to be included in the modern definition of PJI
because standard culture techniques are not 100% sensitive in identifying causative
microorganisms. Several indirect markers of infection were investigated in recent years, resulting
in the need for an updated definition of PJI. An evidence based and weighted scoring system for
PJI using the 2014 definition and modern biomarkers from the literature was published in
2018(81). In the same paper the new (albeit more complex) weight adjusted scoring system for
PJI was validated against an external cohort and compared to the previous 2014 and MSIS 2011
definitions of PJI. The major criteria are unchanged; however, the minor criteria are now
separated into preoperative and intraoperative diagnostic criteria. The minor intraoperative
criteria are used only if the diagnosis of PJI is inconclusive after preoperative criteria have been
evaluated(81). In the minor preoperative diagnosis criteria section, there has been the addition of
serum d-dimer (to some criticism), synovial leukocyte esterase, alpha-defensin (antimicrobial
peptide release by neutrophils in response to bacterial infection), and synovial CRP. The minor
intraoperative diagnostic criteria for inconclusive cases now include positive purulence in
addition to a single positive culture and positive histology. In this seminal paper, the reported
sensitivity of this new scoring system is improved over previous definitions (97.7%), with equal
specificity (99.5%)(81). This new diagnosis has met some criticism however, with only a 68%
agree delegate vote at the most recent 2018 ICM on Prosthetic Joint Infection(82). This
definition is more complicated to implement into clinical practice, not all tests are routinely
available in healthcare systems (for example alpha-defensin), and there is some controversy over
the criteria (for example d-dimer). Thus, its routine use in clinical practice has not yet been
widely adopted. There is an ongoing quest to discover other biomarkers to improve the diagnosis
of PJI, (for example interleukin-6) however, many remain academic at the present time(34).
Even the most updated definitions of PJI have limitations and there is no perfect test to
diagnose PJI(81,83). All definitions of PJI, including the updated 2018 definition, warn that the
diagnosis is not 100% specific and there are patient populations in whom the criteria may be
inaccurate(81). In the 2018 publication by Parvizi et al(81), the authors warn that patients with
slow growing organisms (such as C. acnes, CNS, and others), metal on metal reactions, or
inflammatory arthropathy are at risk of being misdiagnosed. Furthermore, despite a careful
preoperative evaluation, patients who undergo presumed aseptic revision surgery can have
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unexpected positive intraoperative cultures (UPC) that are discovered postoperatively(84,85).
This forms a major basis of the current thesis and will be discussed in a separate section below.
Culture-negative PJI continues to be problematic towards the diagnosis and management
of PJI. It is entirely possible to be diagnosed with PJI by indirect markers of infection (CRP,
ESR, PMN number and %, alpha-defensin, leukocyte esterase, purulence, histology) without
ever identifying a causative microorganism. Identifying the causative microorganism is a critical
aspect of the diagnosis of PJI, as it can guide treatment and antimicrobial therapy. Culturenegative PJI also has a higher rate of treatment failure compared to when a causative
microorganism is identified(86). Historically rates of culture-negative PJI in THA/TKA were
thought to be around 6%, however recent literature suggests that it is higher with a range of 042% and a likely true proportion of 20%(34,87). These infections are typically classified as
delayed or late-onset PJI, with a smaller percentage being early onset or hematogenous(88).
There are multiple postulated reasons for the proportion and variation of culture-negative PJI in
the literature. These include (I) biofilm formation (as discussed previously), (II) the use of
preoperative antibiotics, (III) consideration of a positive culture as contamination, (IV)
inadequate sampling or use of available microbiologic methods, (V) inability to detect known or
previously unknown causative microorganisms for PJI, and (VI) current diagnostic definitions
incorrectly identifying an aseptic case as infected (false positive)(34,87,88).
Modalities to overcome biofilm formation on implants and culture independent methods
of identifying microorganisms, such as molecular techniques, are being pursued in response to
UPC in presumed aseptic revisions and culture-negative PJI. The use of molecular methods to
investigate whether microorganisms play a role in presumed aseptic revisions will be discussed
in a subsequent section and is another major aim of the current thesis.
Sonication of implants removed in revision surgery is a technique that has been
developed to increase the diagnostic yield of cultures in revision THA/TKA. The concept is that
removed implants can be subjected to ultrasound in order to dislodge bacteria from mature
biofilms that have formed on the prosthetic implants. Early studies utilizing sonication for the
culture positive diagnosis of PJI suffered from contamination issues and limited specificity(34).
In a landmark study that used improved technique and sealable sterile plastic containers (not
plastic bags that leak), sonication of revised THA/TKA implants had improved sensitivity with
preserved specificity versus traditional methods to diagnose PJI(89). Recent literature using
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modern PJI diagnostic criteria supports sonication of failed implants in the diagnosis of PJI and a
meta-analysis of molecular methods using implant sonication fluid concluded that sonication
may improve sensitivity and specificity over conventional methods(90,91). However, these
findings are not universal and have been challenged by several authors. Modern, well designed,
large studies have shown that sonication of removed implants does not improve the diagnostic
yield of PJI (false-positives and false-negatives) in presumed aseptic or infected revisions(92–
94).

1.3.5

Treatment and Outcomes of PJI
The goals of treatment are eradication of infection, a pain free, high functioning joint, and

minimizing the morbidity and mortality associated with PJI. Treatment strategies for PJI are
based on the classification of PJI (timing), patient comorbidity profile, surgeon preference, and
the implant, bone, or soft tissue status. The treatment strategies are beyond the scope of this
thesis, however, often necessitate surgical and medical treatment in combination. Treatment
options include debridement, irrigation, and exchange of modular components but retention of
well-fixed components (DAIR), a single-stage revision of all prosthetic components, a two-stage
revision, or in refractory cases, antimicrobial suppression, resection arthroplasty, or
amputation(34,43,51). For a comprehensive review of these strategies I would suggest three
excellent review articles on PJI(34,43,51). All strategies are used in combination with
antimicrobial treatment. Culture identification of causative microorganisms and antimicrobial
sensitivity profiles are the cornerstone of antimicrobial treatment. Regardless of treatment
strategy employed, failure to identify the causative microorganism is associated with worse
outcomes(86).
Both acute hematogenous and early-onset PJI are often treated with DAIR when specific
criteria are met(95). The success rate in terms of infection free survival ranges from 11-100% in
the literature, with an estimated pooled success rate of 61%(95). Many factors influence the
success of DAIR, including time from onset of symptoms, joint involved, and virulence of the
microorganism(s). The standard of care for the treatment of delayed or chronic PJI in North
America is a two-stage exchange (51,96). In the two-stage exchange all prosthetic implants are
removed in order to treat the infection and biofilm, a temporary local antibiotic cement spacer is
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implanted into the joint to allow elution of local antibiotics, systemic antibiotic therapy directed
at the causative microorganism(s) is administered, and weeks to months later, a revision joint is
implanted if infection is thought to be eradicated. In Europe, it has been popular to do this as a
single-stage procedure with an aggressive debridement of infected tissue and antibiotic cement,
but the infected prosthetic joint still has to be removed in order to eliminate the microorganisms
and biofilm(97).
Success rates (cure of infection) for two-stage exchange ranges from 65% to 100% in the
literature, with a success rate of over 80% reported for both one-stage and two-stage exchanges
in a recent systematic review(43,98). Failures in treatment can result in repeat surgeries, chronic
antimicrobial suppression, amputation, or even death. Chronic PJI and its treatment is associated
with considerable patient morbidity and even mortality, as well as poorer patient reported
outcomes compared to primary joint replacement(41,62,67,96,98,99).
It is clear that PJI is a tremendous burden to patients, healthcare systems, and society. It
is also clear that PJI will be more prevalent in the future. In response to this, there has been
considerable funding and scientific efforts aimed at the prevention of PJI. These prevention
strategies can be categorized into preoperative, perioperative, intraoperative, and postoperative
measures(43,100). Again, the details of these prevention strategies are beyond the scope of this
thesis, however readers are directed to two excellent published reviews if interested(43,100).
Further study of PJI prevention is mandatory because despite these measures the incidence of PJI
is not decreasing and may actually be increasing(40–42).

1.4 Unexpected Positive Intraoperative Cultures in Presumed
Aseptic Revision THA and TKA
As described, there remains no perfect method to diagnose PJI in THA/TKA. The
preoperative diagnosis of PJI is important because the surgical treatment of aseptic and septic
failures differ substantially. Unexpected positive intraoperative cultures (UPC) can occur in
presumed aseptic revisions(84,85,101). An UPC is by definition a positive culture(s) obtained
during a revision THA/TKA surgery that was presumed to be aseptic. The surgeon becomes
aware these single or multiple UPC postoperatively. The current definition of PJI considers 2
cultures of the same microorganism as diagnostic for PJI(38,81). UPCs are likely to remain a
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problem since it has been postulated that a proportion of presumed aseptic failures are actually
undiagnosed PJI(102–104). However, the true incidence, clinical significance, and optimal
treatment of UPC in presumed aseptic revisions is not clear in the literature(105).

1.4.1

Prevalence
There are a small number of studies reporting on the prevalence of UPC using

conventional cultures methods (culture of joint fluid aspirate, swabs, periprosthetic tissue) and
the true incidence remains unclear. A recently published review on UPC in presumed aseptic
revision THA/TKA demonstrated a mean prevalence of 10.5% (379 UPC in 3605 presumed
aseptic revision cases), however this varied considerably (4-38%)(105). The review included 10
studies published after the year 2000 that reported on the prevalence of UPC in presumed aseptic
THA/TKA failures, as well as their treatment and outcomes. The mean follow-up was 26 months
and the prevalence of UPC in hips was nearly two times more common than knees. The majority
of the UPC were caused by low virulence microorganisms, such as CNS and C. acnes(105). A
summary of study characteristics and outcomes can be found in tabular form in the published
review(105).
An early retrospective study by Padget et al(106) reported an UPC prevalence of 30.4%
in 138 presumed aseptic THA. They used a minimum of 6 intraoperative culture specimens
(swab and tissue) and found that the majority (35 hips) of these were a single UPC. Unlike many
studies, these authors did report on the outcomes of a single positive UPC. Conversely, a
subsequent retrospective study reported a 11% rate of UPC in presumed aseptic revision
(31/275), however this study only considered PJI diagnosed by UPC ( 2 UPC with the same
microorganism growing on solid medium)(35). In one of the very few prospective studies Atkins
et al(75) evaluated 297 presumed aseptic THA and TKA and found a that 27.9% of cases had
UPC (47 had 1 UPC, 8 had 2 UPC, 28 had 3 UPC). However, the authors considered the vast
majority of 1UPC and 2 UPC cases to be false positives based on histology and recommended
that histology and multiple tissue samples be obtained based on statistical modelling.
In contrast, another early retrospective study looking at revision TKA found that only 4%
(5/133) were diagnosed with PJI based on UPC(107). However, the prevalence UPC in this study
may have been lower due to the definition used (only  2 UPC with the same microorganism
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grown on solid medium). In 2007 Berend et al.(108) reported on 106 presumed aseptic failed
THA cases and reported an UPC prevalence of only 6.8% (2/7 of these were gram stain positive
only). The authors accounted for the low prevalence with a throughout preoperative evaluation
and use of swabs in addition to tissue cultures. Similarly, a large retrospective, 3 centre study
published in the same year evaluated 692 presumed aseptic failed TKA revisions and found a
5.9% (41/492) rate of UPC(101). The authors reported that 29/41 were single UPC with no other
signs of infection and concluded that these were false positives. Of the 41 UPC, 8 had 2 UPC
with the same microorganism and 4 had 1 UPC with other signs of infection (elevated
ESR/CRP). Parvizi et al.(102) published a retrospective study in 2011 looking at 314 failed THA
with the diagnosis of AL to evaluate serum ESR and CRP parameters. Intraoperative cultures
(minimum 3 fluid/and or tissue) were obtained in 169 of these cases and 8.3% (14/169) had at
least a single UPC grown on solid medium (excluded broth).
However, Ribera et al.(109) performed a prospective evaluation of 89 presumed AL cases
(60THA/29TKA) comparing periprosthetic tissue versus implant sonication cultures in the
diagnosis of PJI. The authors took a minimum of 5 tissue cultures and considered  2 UPC with
the same microorganism growing on solid medium to be diagnostic of PJI, but reported on cases
with a single UPC as well. In contrast to the previous 2 retrospective studies, the incidence of
UPC in tissue samples was 38% (34/89); 12 of these were  2 UPC and 22 of these were single
UPC(109). Two recent prospective studies compared the ability of conventional operative
cultures versus sonication fluid cultures to diagnose PJI in presumed aseptic failures
(AF)(92,103). In 198 cases of presumed AL an incidence of PJI diagnosed by UPCs was 5.4%
using conventional culture methods(103). However, only  2 UPC with the same microorganism
growing on solid medium were considered with the exception of two specific virulent
microorganisms (11 additional single UPC excluded). Kempthorne et al.(92) reported on 56 AL
cases versus 53 other AF controls and found an incidence of UPC (including singe) of 15% in
the AL cohort and 2% in the control cohort.
Finally, two retrospective studies were published in 2017(84,94). Jacobs et al.(84)
reviewed 679 presumed AF THA/TKA cases with a minimum of 3 tissue samples and found that
10% (12.1% THA and 7.9% TKA) of cases had a UPC diagnosis of PJI with  2 UPC of the
same MO on solid medium (excluded and did not report on single UPC). Van Diek et al.(94)
reported a prevalence of PJI diagnosed by UPC ( 2 UPC with the same MO on solid medium,
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with the exception of a single S. aureus UPC) of 18.6% (33/177) using a minimum of 6 tissue
cultures in presumed aseptic revisions. Again, this study did not consider a single UPC (with
exception of S. aureus) to be significant and did not report on this cohort of patients.
The reported prevalence of UPC in presumed aseptic THA/TKA failures in the literature
varies considerably. This variability is due to differences in preoperative evaluation, definitions
of PJI (many studies pre-dated or did not use modern MSIS criteria), diagnoses for the AF cohort
(AL seems to have higher rate of UPC), definitions of UPC used in each study ( 2 UPC with the
same MO on solid medium versus single UPC versus solid medium or broth), type and number
or cultures taken, study design (retrospective versus prospective), and often small sample sizes,
differing microbiological laboratory protocols, and potential contamination(105).

1.4.2

Treatment and Outcomes
Far fewer studies report on treatment and outcomes of UPC compared to the number

reporting on prevalence. There is no consensus on when and how UPC should treated. The
majority of treatment and outcome studies in this patient population are retrospective in nature
and have limited sample sizes. Treatment protocols included standard prophylactic antibiotics, 46 weeks of intravenous (IV) and/or oral (PO) antibiotics, months of antibiotic treatment, or
chronic antibiotic suppression(105). Although controversial, most authors would agree that  2
UPC with the same microorganism should be treated with 4-6 weeks of antibiotics and can
expect to have a satisfactory outcome with 80-100% survival at short term follow-up. Low
virulence microorganisms common to UPC and short-term follow-up (mean 26.1 months) are
thought to contribute to this reported infection-free survival(105). The clinical significance and
treatment of single UPC are a topic of debate with no clear consensus to date.
A successful outcome or survival in these studies was often defined as absence of
recurrent or new PJI and/or no revision surgery for infection-related failure. Padgett et al.(106)
treated only 11/41 of UPC in hips with 6 weeks of IV and/or oral antibiotics. At mean follow-up
of 48 months only 1 case required revision for PJI, leading the authors to question the
significance of a single UPC with a low virulence microorganism and to rely on histology in
these cases. Tsukayama et al.(35) reported on 31 presumed AL THA cases diagnosed with PJI
based on  2 UPC with the same microorganism on solid medium. All were treated with 6 weeks
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of IV antibiotics and at a mean of 3.5 years reported a 90% success rate (3/31 required revision
for PJI with same microorganism as UPC and 3 additional cases showed evidence of loosening
of x-rays). Segawa et al.(107) reported on 5 TKA revised for presumed AL diagnosed with PJI
based on  2 UPC with the same microorganism on solid medium (all CNS). All 5 cases were
treated with 6 weeks of IV antibiotics and at a mean of 4 years survival was 100% (one x-ray
consistent with tibial baseplate loosening).
In 2005 Marculescu et al.(110) published a retrospective review of the 16 of 509 PJI
cases preformed at their institution that were diagnosed by  2 UPC (same MO on solid medium)
in presumed aseptic TKA revisions. To be included in the study, these 16 patients had to be
treated with IV antibiotic strategies that lasted < 6 weeks. Treatment in the study varied; 8 cases
were treated with IV antibiotics followed by chronic oral suppression, 4 cases were treated with
IV antibiotics alone, 1 case was treated with oral suppression alone, and 3 cases received no
antibiotic treatment(110). The treatment mean duration in the 12 patients that received IV
antibiotics as part of their regimen was 28 days (range 2-42) and the mean duration in the 4
patients treated with IV antibiotics alone was 15 days (2-28 days). At a mean follow-up of 1057
days (731-1969 days) the 5-year infection free survival was 89% (95% CI 47-98%). The authors
concluded that PJI diagnosed by  2 UPC with the same microorganism of low virulence have
favorable outcomes with component retention and IV antibiotic treatment strategies of < 6
weeks.
Berend et al.(108) considered all 7 UPC in revision THA as significant treating with 6
weeks of IV antibiotics (PO antibiotics for 2 that were gram stain positive only), and reported no
failures for infection at a mean of 31.6 months. They concluded that all UPC should be treated as
significant but advised that more tissue cultures should be taken to allow false positives to be
identified (may not need treatment). In the large retrospective 3 center study by Barrack et
al.(101), the 41 presumed aseptic TKA that had at least one UPC were followed for a mean 45
months post revision. Twenty-nine of these cases had a single UPC with no other signs of
infection and were considered probable false positives; of these only 5 were treated with 4-6
weeks of antibiotics. Twelve UPC cases had signs of infection; 8 with 2 UPC of the same
microorganism and 4 with a single UPC on solid media with elevated ESR or CRP elevated. Of
these, 11 were treated with 4-6 weeks of antibiotics. No failures (revision or PJI) were
encountered for the 29 cases considered false positives (single UPC with no signs infection), but
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3 of 12 cases with signs of infection required revision (2 for PJI and 1 for AL). The authors
concluded that cases with a single UPC and no other signs of infection can safely be regarded as
false positives and don’t require treatment. Similarly, Dramis et al.(111) retrospectively reviewed
56 revisions (majority hip and knee) that had at least a single UPC of C. acnes. Only 12 of these
received 6 weeks of antibiotic therapy as advised by as infectious disease specialist (all sensitive
to penicillin) and patients were followed for a mean of 20.5 months. Forty cases had isolated
UPC of C. acnes only (8 had  2 UPC) and 16 cases were mixed UPC. Only 1 required revision
due to PJI leading the authors to question the significance of an UPC with C. acnes.
Saleh et al.(85) grouped THA/TKA UPC patients into those with a single UPC
considered contaminants and not treated with antibiotics (44 cases) versus those with UPC(s)
that were treated with antibiotics. The antibiotic cohort was further subdivided into those that did
(14 PJI-positive) and did not (45 PJI-negative) meet MSIS criteria for infection. The minimum
follow-up was 1 year with a mean of 51 months. Sixty-six percent of the antibiotic cohort
received IV antibiotics, 17% PO antibiotics, and 17% both IV and PO antibiotics for 4-6
weeks(85). Patients were treated with antibiotics as per advice of an infectious disease specialist
based on institutional criteria. Nine percent of the ‘false-positive’ no antibiotic treatment cohort
developed PJI vs 20% in the antibiotic treatment cohorts (difference not statistically significant).
Subsequent PJI in the false-positive no antibiotic treatment cohort were all caused by different
microorganisms versus the UPC. In the antibiotic treatment cohort 12/14 of subsequent PJI was
caused by the same microorganism as the UPC. Additionally, there was a higher revision rate in
the 1 UPC PJI-negative antibiotic group versus the PJI-positive antibiotic group (22 v 14%), but
again this difference was not significant. The authors concluded that the 1 UPC cohort not
treated with antibiotics seemed to be false positives. However, they cautioned that a single UPC
may indicate infection (even MSIS PJI-negative) when associated with high virulent
microorganisms or other signs of infection, and that these should be treated.
Kempthorne et al.(92) prospectively evaluated 106 failed hips and knees (56 for AL and
52 for other presumed aseptic causes) for a mean follow-up of 9.7 months. They treated 4/9 of
the UPC with antibiotics for 6 weeks and had no reoperations due to infection at short term
follow-up. It should be noted that a single UPC was included in the study. In contrast, the
prospective study by Fernandez-Sampedro et al.(103) reported a much higher failure rate,
however the UPC PJI cohort in this study had to have ≧2 tissue UPC of the same microorganism

21

(exception is S. aureus or Staphylococcus lugdunensis because of high virulence). Eleven of the
24 with ≧2 tissue UPC of the same microorganism were treated with antibiotic therapy and
minimum follow-up was 2 years (mean 36 months). They found that 37.5% of the ≧2 tissue
UPC cohort failed by 2 years versus only 1.1% of the AL cohort(103). Interestingly, the authors
found that antibiotic treatment did not improve survival in the ≧2 UPC cohort. Additionally, 11
patients with a single UPC (not diagnosed with PJI) did not fail.
The last study to look at survival in UPC was a large retrospective study of presumed AF
hips and knees with a minimum follow-up of 2 years(84). Again, only patients with ≧2 tissue
UPC of the same microorganism were included in the UPC cohort. Sixty-five percent of the hips
and 53% of the knees were treated with antibiotics based on the microorganism and infectious
disease specialist (no standard protocol). The authors reported survival at 2 years for the UPC PJI
cohort versus the aseptic cohort (aseptic included those with a single UPC). For THA the
difference was non-significant (92% versus 94%) but for TKA the UPC cohort had worse
survival (88% versus 98%).
The only study to look at any type of functional outcome in this patient population was
Tsukayama et al. in 1996(35). At a mean follow-up of 3.5 years the 31 UPC PJI (≧2 tissue UPC
of the same MO) the mean Harris Hip Scores were 79 postoperatively compared to 45
preoperatively(35).

1.4.3

Current state of the literature
The current literature is inadequate to inform surgeons or clinicians in a meaningful way

on the prevalence, clinical significance, preferred treatment, or outcomes of UPC in presumed
aseptic revision THA/TKA(35,75,106–111,84,85,92,94,101–103,105). Reasons for this include
differences in patient population, diagnoses for failure (AL seems to have higher rate of UPC),
preoperative evaluation, preoperative definitions of PJI (many studies pre-dated or did not use
modern MSIS criteria), definitions of UPC used in each study ( 2 UPC with the same MO on
solid medium versus single UPC versus solid medium or broth), UPC patients excluded, type and
number or cultures taken, microbiologic laboratory protocols, study design (retrospective versus
prospective), and the often short follow-up times, small sample sizes in the majority of studies,
and potential contamination(105).
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The significance of a single UPC is even more unclear, with contradictory findings in the
literature. However, two recent retrospective, but well-designed studies would suggest that even
a single UPC may be important, may warrant treatment, and has the potential to impact
outcomes(85,112). Furthermore, since many studies excluded a single UPC or those grown in
broth only, data on this patient population is lacking.
Clearly more data is needed to better understand the clinical significance, expected
outcomes, and optimal treatment for patients with UPC in presumed aseptic revision THA/TKA.

1.5 Molecular Methods in Presumed Aseptic Revision THA and
TKA
The identification of bacterial microorganisms by conventional culture techniques
remains the gold standard in the diagnosis of PJI and has important treatment implications.
However, cultures lack sensitivity and fail to identify causative microorganisms in a meaningful
proportion of cases(86,87,113).
Thus, the use of culture-independent molecular methods to detect bacterial DNA of
microorganisms in PJI has be a topic of interest in the last 1-2 decades. Polymerase chain
reaction (PCR) based molecular methods have the potential advantages over traditional cultures
of being more sensitive, faster, having the potential to identify non-culturable microorganisms,
and not being influenced by prior treatment such as antibiotics(104,114–116). Most molecular
studies have looked at PCR and the diagnosis of PJI, however, molecular studies have also
identified microorganisms on implants of presumed aseptic failures(116–120).
Furthermore, it has been postulated that presumed aseptic THA/TKA failures may be
undiagnosed PJI caused by low virulent, difficult to culture bacterial microorganisms or a proinflammatory response to colonization of these microorganisms on prosthetic implants(102–
104,109). Proposed mechanisms for this hypothesis include formation of biofilms of prosthetic
implants and the implications of this, use of prophylactic antibiotics, and difficult to isolate or
rare pathogens that traditional microbiologic laboratory techniques may fail to identify(104).
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1.5.1

Molecular Methods in the Diagnosis of PJI
The results of molecular methods, largely PCR based, in the diagnosis of PJI have been

contradictory. Molecular PCR analysis of a variety of sample types (tissue, aspirate fluid,
sonication fluid of implants) has shown a wide range of sensitivity (50-92%) and specificity (6594%) in the diagnosis of PJI(115,121). A systematic review and meta-analysis of the literature in
2013 including 14 studies showed that the pooled sensitivity and specificity for PCR assays in
the diagnosis of PJI were 0.86 and 0.91, with tissue samples having the highest sensitivity and
sonication implant fluid having the highest specificity(121). An updated systematic review and
meta-analysis including studies from 2013 to 2017 showed a decreased pooled sensitivity (0.76)
and an increased specificity (0.94) compared to the 2013 results(115). Interestingly, the authors
of this 2018 meta-analysis did not find that the use of implant sonication fluid samples improved
the diagnostic yield with molecular methods. In a large number of studies sonication of implants
designed to dislodge bacteria from the biofilm has been shown to increase the sensitivity of PCR
based methods(91,118,122,123). However, this is not universal and well-designed molecular
studies have shown no difference versus traditional cultures of sonication fluid and even worse
performance than standard tissue cultures in some instances(78,113,115,124). Reasons for the
reduced sensitivity but increased specificity reported by the authors of the 2018 meta-analysis
include the increased use of multiplex PCR techniques as opposed to universal PCR (see below),
differences in sequencing techniques used, modern definitions of PJI, stricter definitions of PCR
based PJI and lab based techniques to reduce false positives, different types of samples, and
differences in the number of samples used(115).
Early PCR based techniques identified bacterial DNA but was not able to identify
specific species of bacteria to be meaningfully compared to culture results(120). The use of so
called broad-range or universal PCR targets the 16S ribosomal RNA gene (16S rRNA), that is
highly preserved and universally present in bacterial microorganisms. Most molecular PJI studies
using modern 16S rRNA PCR techniques amplify the 16S rRNA gene and then identify the
micoorganism by sequencing the amplified DNA. In contrast to the proposed advantages of
molecular techniques, disadvantages of 16S rRNA PCR include the cost/need for sequencing,
issues of contamination (false positives) and false negatives (difficulty identifying anaerobes),
and difficulty identifying multiple organisms in polymicrobial infections(34,115,125). Promising
rapid 16S rRNA PCR based methods have been developed, as have methods to improve
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sensitivity and specificity(113–115,125). In an attempt to improve on the limitations of 16S
rRNA PCR, “multiplex PCR” has been developed and studied in THA/TKA PJI(124,126,127).
Multiplex PCR uses multiple primer assays that are designed to target DNA sequences of
specific bacterial microorganisms thought responsible for PJI in THA/TKA. Assays for multiple
bacterial microorganisms have been developed, recently including anaerobes such as C. acnes
and other microorganisms thought to be missed (lower sensitivity) by 16S rRNA PCR(126,127).
Polymicrobial infections are also less of a problem for multiplex PCR. However, a limitation is
that multiplex PCR techniques can be less sensitive for all microorganisms present and miss
microorganisms they do not target or that were not thought to be involved in PJI. A recent metaanalysis shows that specificity may have improved with multiplex PCR, but sensitivity is
decreased and reports of 16S rRNA PCR methodology with similar or better specificities do
exist(115).
Given that modern definitions of PJI and novel biomarkers (such as alpha-defensin) have
a greater diagnostic ability to that of the pooled results of recent molecular studies, the role of
molecular methods in PJI is not yet clear. It appears that molecular methods have a clear value in
culture-negative PJI and in patients who have been on antibiotics and may potentially improve
our ability to diagnose PJI in the future(78,115,116,128). However, the current meaning of these
results, contradictory findings, evolving techniques, and potential for contamination continues to
be an issue(78,115,116,128).

1.5.2

Molecular Methods and Identification of MO in

Presumed Aseptic Revisions
UPC in presumed aseptic revisions, the large proportion of culture-negative PJI, and
several molecular studies support the theory that a significant proportion of AF in THA/TKA
may be associated with microorganisms and/or unrecognized PJI. In comparison to the
evaluation of molecular methods in the diagnosis of PJI, there has been less literature evaluating
the use of molecular methods to detect microorganisms in cases of presumed AF or AL. The
majority of the data on molecular methods in AF come from studies that evaluate PJI in revision
THA/TKA, however molecular studies evaluating presumed AF cases do exist(78,113,125–
132,116–120,122–124). However, there is considerable debate on the topic with conflicting
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findings. Molecular literature supporting the detection of bacterial microorganisms and the
potential role of undiagnosed PJI in presumed aseptic revision exists and continues to be
published(116–120,122,123,129). However, several authors question the relevance and meaning
of PCR based detection of microorganisms and others do not support detection of true positive
microorganisms or undiagnosed PJI in presumed AF with the use of molecular
methods(78,113,124–128,130–132).
In 1999 Tunney et al.(120) prospectively evaluated 120 THA septic and aseptic revisions
using 16S rRNA PCR (no sequencing) and found tissue and implant sonication fluid (ISF)
cultures diagnosed infection in only 22% of cases, whereas PCR of ISF identified bacterial DNA
in 73% of cases. They concluded that the incidence of infection is grossly underestimated in
previously presumed AF in THA but did not use sequencing and were unable to correlate
molecular data to tissue cultures. Similarly, Clarke et al.(119) reported on 31 presumed aseptic
revision THA cases that were all tissue culture negative and showed that 46% of these patients
were positive for microorganisms using 16S rRNA PCR. However, the threshold for a positive
PCR result was lower than used in modern studies, and the authors demonstrated a 29% falsepositive contamination rate concluding that PCR was not specific enough to be used in the
diagnosis of PJI. In contrast, a similar study prospectively evaluating presumed AL cup failures
in 24 THA cases using 16S rRNA PCR methods showed that both tissue cultures and PCR were
negative in all patients except 1 and that low virulence infections are likely not the usual cause of
AL in THA cups(132). However, in 2008 Kobayashi et al.(122) prospectively evaluated 52
THA/TKA patients with dual assay PCR (both 16S rRNA PCR and Staphylococcus species
specific primers), 85% of which were presumed AL preoperatively. They showed that 12% of
culture-negative AL patients were PCR positive and that PCR was more sensitive than tissue or
ISF cultures at detecting microorganisms. The authors reported that perhaps the lower incidence
of 12% in their study was due to stringent criteria for a positive PCR result and control of
contamination(122). Though soon after Moojen et al.(131) prospectively reported on another
cohort of 176 presumed AL THA failures in a multicenter study using 16S rRNA PCR and
multiple tissue and fluid samples. Using a very conservative criteria of  3 separate
microorganism specimens as true positive for infection, they found that in the uninfected group
(<2 specimens positive for microorganisms) tissue culture was falsely positive in 26% of cases
and PCR was false positive in 20% of the cases. Additionally, they reported that 4% to 13% of
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presumed aseptic revision cases are suspected or true infections (PCR more sensitive in true
infections), although of seemingly little clinical effect at 1-year follow-up.
In one of the many studies on the subject matter out of the Mayo Clinic, Gomez et
al.(113) evaluated 366 septic and aseptic THA/TKA revisions and showed that 16S rRNA PCR
analysis of ISF was statistically equivalent to traditional cultures of ISF, tissue, and synovial
fluid. Using strict criteria and careful methodology (use of real-time PCR threshold to decrease
false positives and software to detect microorganisms in polymicrobial infections) to maintain
the specificity of PCR, the authors also showed that only 5/231 AF were positive by PCR
(similar to cultures), and did not support the hypothesis that AF are often undiagnosed PJI. A
follow-up study out of the Mayo Clinic again retrospectively evaluated a large cohort of both
aseptic and septic revision THA/TKA (434, 290 diagnosed as AF) with a rapid, multiplex
genus/group specific, real-time PCR assay panel targeting bacterial microorganisms that are
typically associated with PJI, including anaerobes (new addition versus previous)(127). The
authors hypothesized that the new multiplex PCR of ISF would improve sensitively and rapidly
diagnose PJI and compared results of PCR to those of cultures (ISF, tissue, and aspirate). The
authors concluded that the multiplex PCR of ISF was more rapid and sensitive with similar
specificity compared to cultures in diagnosis of PJI, and the high specificity of the assay
suggested that typical bacteria may not be the cause of aseptic implant failure(127). It should be
noted that multiplex PCR can only detect bacteria that the primers target, so they were at risk of
failing to detect non-traditional PJI microorganisms (trade-off between sensitivity and
specificity). Portillo et al.(124,130) published 2 prospective studies using multiplex PCR in both
septic and aseptic revisions. The AF cohort in both studies had no false positive microorganisms
identified using PCR, with equivalent and improved sensitivity compared to ISF culture
methods. Multiplex PCR in these studies did not support microorganisms common to PJI as a
causative factor in aseptic failures. Importantly though, the assay used did not detect anaerobes
such as C. acnes or Corynebacterium (common to UPC), and the authors had very stringent
criteria for what they considered a “contaminant”(124,130).
Bjerkan et al.(78) performed a prospective study using 16S rRNA PCR in 54 loose
THA/TKA implants to diagnose PJI (21 preoperative diagnosis of infection) with multiple
standardized specimens collected and a special emphasis on minimizing the risk of contaminants
and false-positive results. Using real-time 16S rRNA PCR methods to establish stringent “true-
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positive” thresholds, surprisingly the authors reported that tissue cultures (especially interface
membrane) were more sensitive than PCR methods. Furthermore, the specificity of PCR was
able to be maintained with only 2/216 samples in 2/36 AF patients positive and defined these as
false positive contaminants as per study criterion(78) . However, other authors that employed
careful methodology using both 16S rRNA PCR and multiplex PCR methods when prospectively
evaluating larger cohorts of septic and aseptic THA/TKA revisions have supported PCR
molecular methods as more sensitive in PJI and better able to detect MO in previously presumed
AF cases with ISF and scraping of implants(123,129). Esteban et al.(123) and other authors have
warned that pathogens detected in presumed AL and AF patients should not all be confidently
disregarded as contaminants (as was done by Bjerke at al. 2012), and assays used is many of
these studies had low sensitivities for detecting anaerobes and C. acnes.
More recently, Bereza et al.(117) showed using 16S rRNA PCR in a prospective study of
37 THA/TKA revisions that PCR identified a variety of bacterial microorganisms in patients
with negative cultures, and that histology supported infection in 41% of these. Likewise, authors
applying modern MSIS criteria and 16S rRNA PCR analysis of ISF versus standard cultures in
preoperatively assumed aseptic revisions demonstrated that microorganisms were identified by
PCR in 13/58 AF patients(118). Six of 9 were considered insignificant based on criteria of <2
specimens positive for the same microorganism, but authors urged that further molecular study in
AL is warranted. Conversely, Ryu et al.(126) showed in a retrospective study of 87 TKA
revisions (with a major focus on PJI) that standard tissue cultures had a higher sensitivity than
multiplex PCR tissue culture (69% versus 16%). However, these results need to be interpreted
with caution and the authors also acknowledged limitations of the study that can be corrected and
investigated in the future. Potential reasons for such a low sensitivity of PCR tissue culture in the
study include that only a single tissue culture was taken for PCR analysis, that microorganisms
are in biofilms and may not be equally distributed in the periprosthetic tissue, that implant
membrane tissue was not the tissue used for PCR, and that specimen age may have played a role
(retrospectively evaluated)(126). However, a large well-designed prospective multicenter study
of 264 suspected THA/TKA PJI (215 confirmed PJI by Infectious Disease Society of America
criteria [IDSA]) evaluating the ability of 16S rRNA PCR gene assays to diagnose PJI used
multiple cultures (tissue/fluid) and showed poor sensitivity versus IDSA criteria and standard
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tissue cultures(125). Additionally, the PCR assay used was not superior to cultures at detecting
microorganism in AF cases, and was poor at detecting C. acnes (only 11% vs tissue cultures).
What is clear about the literature on molecular methods and microorganism in AF is that
the data is controversial. To add to this controversy, two large studies using modern “NextGeneration Sequencing” (NGS) and “Shotgun Metagenomics” approaches again show
conflicting results. In another study out of the Mayo Clinic, Thoendel et al.(128) applied a
comprehensive metagenomic shotgun approach (all of nucleic acid in the sample extracted and
sequenced in order to identify any potential organism) retrospectively to a large sample (408
revisions) of previously collected and stored aseptic and septic THA/TKA revisions. Again,
using IDSA criteria for PJI, one of the major aims of the study was to investigate the potential
role of unidentified microorganisms in otherwise seemingly aseptic failures. The authors found
that only 3.6% (7/195) AL cases were considered microorganism positive using refined criteria
(large number of contaminants common to metagenomic sequencing were excluded), thus not
supporting the theory of a high prevalence of microorganisms in seemingly aseptic revisions.
However, there were additional microorganisms identified in about 10% of culture-positive PJI,
and microorganisms identified in in 43.9% of culture-negative PJI(128). Conversely, Tarabichi et
al.(116) published a prospective evaluation of 65 revisions (with 17 primary THA/TKA controls)
evaluating the accuracy of NGS in identifying microorganisms causing PJI, with a special
interest in culture-negative PJI. NGS, similar the metagenomic shotgun methods, is capable of
sequencing all DNA present in a sample. The authors found that the sensitivity of NGS was far
superior to tissue culture in PJI, and that NGS identified microorganisms in 80% of culturenegative PJI. In MSIS PJI-negative aseptic revisions NGS identified microorganisms in 25% of
patients (9/36) that were tissue culture negative, thus supporting the role of microorganisms in
both culture-negative PJI and “aseptic” failures. However, both methods are suspect to
contamination issues, and the clinical significance of the identified microorganisms in AF are
largely unknown(116,128).
A lack of a gold standard for the diagnosis of PJI makes interpretation of these findings
difficult. A majority of early studies did not use a widely accepted standard to diagnose PJI,
(such as MSIS) instead using tissue cultures as the gold standard for diagnosis of PJI. The
different PCR molecular methods used, criteria used for true-positive PCR specimens or PJI, and
control of ‘contaminants’ makes comparing results difficult as well. Limitations of 16S rRNA
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PCR, multiplex PCR, and newer whole DNA approaches are challenging as well (as outlined
above). Additionally, the utility of sonication of implants is also inconclusive. Scraping implants
has been shown to increase the diagnostic culture yield in revisions and to be a viable alternative
to sonication, with the advantages of being less expensive and at less risk of contamination
associated with sonication protocols(79,129). There have been conflicting results on the value of
scraping material from implants and tissue samples with molecular techniques(78,115,126,129).
However, the best combination of results with PCR molecular methods have been observed
when at least 5 samples are studied, a limitation to most scraping and tissue sample studies with
PCR(115,129,133). Additionally, sonication is also unable to determine if there are specific areas
on prosthetic implants that microorganisms are more likely to be found (important information).
A prospective molecular study with stringent control of contamination evaluating the material
obtained by scraping multiple predetermined sites of prosthetic implants from presumed aseptic
failures is thus warranted and may provide valuable information. There is a paucity of literature
looking at the clinical outcomes or survival of presumed aseptic failures with microorganisms
identified by molecular methods, and the clinical significance remains unclear(116,124,131).
This clearly needs further evaluation.
The prevalence, role, and clinical significance of microorganisms identified by molecular
methods in presumed aseptic failures in THA/TKA remains unclear. Given the enormity of the
implication that microorganisms and/or unrecognized PJI may be associated with currently
presumed aseptic failures, this area necessitates further study.
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Chapter 2

2.

Thesis Rationale and Objectives

2.1 Rationale
The literature review in Chapter 1 revealed that the incidence, optimal treatment, clinical
significance, and outcomes of UPC in presumed aseptic revision THA and TKA remains unclear.
Given the reported prevalence and projected increases in revision surgery, this remains a
clinically important and challenging problem. The literature is limited and conflicting, and larger
studies are needed. This serves as the basis for the retrospective database portion of this thesis.
Furthermore, culture-independent molecular methods have several advantages over
traditional cultures and have gained popularity because a significant proportion of PJI remains
culture-negative (fails to identify a causative microorganism). Although the majority of
molecular studies investigated the evaluation of PJI, molecular studies investigating presumed
aseptic failures have identified microorganisms on failed implants. It has been postulated that
microorganisms may play an important role in presumed aseptic failures and that a proportion of
these may be undiagnosed PJI. However, the results of modern molecular studies in presumed
aseptic revision THA and TKA, particularly those with stringent control of contamination, are
contradictory. The prevalence, clinical significance, and role of microorganisms identified in
presumed aseptic revisions using molecular techniques remains unclear. Additionally, no
molecular study has investigated if there are specific areas on the prosthetic implants that
microorganisms are more likely to be found. The implications of microorganisms having a role
in previously presumed aseptic failures are enormous and this clearly deserves further
investigation, serving as the basis for the prospective pilot molecular study portion of the current
thesis.
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2.2 Overview
This thesis is written in an integrated article format, with each chapter corresponding to a
separate research study corresponding to the research objectives below. Chapter 3 and 4 will
investigate the prevalence of UPC in presumed aseptic revision THA and TKA, as well as the
infection-free implant survival for this patient population. Chapter 3 will be a study reporting on
UPC in presumed aseptic revision THA and Chapter 4 will be a separate study reporting on UPC
in presumed aseptic revision TKA. We elected to report on THA and TKA separately because
the prognosis of hips and knees has recently been shown to differ in this patient population(1).
These studies are retrospective reviews of a prospectively collected database at a single highvolume academic institution. To our knowledge, both will represent the largest series of UPC in
revision THA and TKA in the literature and will be a valuable contribution to the current body of
knowledge.
Chapter 5 is a prospective pilot study using modern molecular techniques in presumed
aseptic revision THA and TKA at our institution, with an emphasis on stringent control of
contamination. We will be investigating if and how frequently microorganisms are present on
implants of presumed aseptic revisions, as well as where they are found on the implants and if
their presence is associated with reason for revision. Our expectation is that data from this pilot
study will be used to perform power calculations, design, and fund large definitive studies to
determine the role and clinical implication of microorganisms identified by modern molecular
techniques in presumed aseptic revisions. Due to the unprecedented COVID-19 pandemic and
state of emergency, the completion of the molecular portion of this study has been postponed.
All samples for molecular analysis are collected but we are awaiting lab access in order to
complete the study. Please refer to Chapter 5 for full details and our progress to date.
Finally, Chapter 6 is the concluding chapter of this thesis. The main findings and
conclusions of this work will be summarised, as well and limitations and future directions.

2.3 Specific Objectives
The primary purpose and secondary aims of each study are outlined below.
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2.3.1

Prevalence and Outcomes of UPC in Presumed Aseptic

Revision THA
The primary purpose of this study was to:
(I) Determine the prevalence of UPC in presumed aseptic revision THA and to report on
the infection-free implant survival for this cohort.
Secondary aims included:
(I) Comparing infection-free implant survival between patients with 1 versus 2 UPCs.
(II) Comparing infection-free implant survival between patients with a single UPC
treated with antibiotics versus not treated with antibiotics (considered a contaminant).
(III) Reporting on the infection-free implant survival for those with a single
Cutibacterium acnes UPC.

2.3.2

Prevalence and Outcomes of UPC in Presumed Aseptic

Revision TKA
The primary purpose of this study was to:
(I) Determine the prevalence of UPC in presumed aseptic revision TKA and the
infection-free implant survival for this cohort.
Secondarily aims included comparing:
(I) The infection-free implant survival between patients with 1 versus 2 UPCs.
(II) The infection-free implant survival between patients treated with antibiotics versus
not treated with antibiotics (considered a contaminant).

2.3.3

Do Microorganisms Have a Role in ‘Aseptic’ THA and

TKA Implant Failure? A Prospective Molecular Study
Using modern molecular and sequencing methods with an emphasis on the stringent control of
contamination our aims are to:
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(I) Determine the frequency and type of bacterial microorganisms on prosthetic implants
from presumed aseptic THA and TKA failures, and compare the microorganisms
identified by molecular methods to those of standard cultures.
(II) Determine the type of implants and location on the implants that bacterial
microorganisms are found.
(III) Determine if the presence of bacterial microorganisms is associated with the reason
for revision.
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Chapter 3
3.

The Prevalence and Outcomes of Unexpected Positive

Intraoperative Cultures in Presumed Aseptic Revision Hip
Arthroplasty
3.1 Introduction
Total hip arthroplasty (THA) is a highly successful and cost-effective treatment for endstage arthritis(1,2). Approximately 500,000 THA are performed in North America annually(3,4),
and this number is projected to increase substantially(4,5). Up to 12% of primary THA needs
revision surgery by 10 years (6), and the number of revisions is also projected to increase
markedly(4,5).
Periprosthetic joint infection (PJI) is a leading cause of revision at a rate of approximately
2% for primary THA(7–9). PJI is a dreaded complication associated with substantial morbidity
and cost, and the rate has remained constant over time(7,8,10). Despite considerable scientific
efforts, there remains no perfect test to diagnose PJI(11–13) and it has been postulated that a
significant proportion of presumed aseptic failures are actually undiagnosed PJI(14–16). This
results in the occurrence of unexpected positive intraoperative cultures (UPC) in presumed
aseptic revision THA. UPC pose a challenging clinical problem because the surgical treatment of
aseptic versus PJI-related failure differs substantially, and surgeons only become aware of the
UPC after the presumed aseptic revision surgery.
The prevalence of UPC in presumed aseptic revision in the literature varies considerably
(4-38%)(17). There is no consensus on the optimal treatment of UPC and the consequence in
terms of infection-free implant survival remains unclear(14,17–21). The clinical significance of
PJI diagnosed by UPC in presumed aseptic revision remains highly debated in the literature, and
the significance of a single UPC is even more unclear(14,17–20,22). The literature on UPC is
limited and larger studies are needed(17).
The primary purpose of this study was to determine the prevalence of UPC in presumed
aseptic revision THA and to report on the infection-free implant survival for this cohort.
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Secondary aims included (I) comparing infection-free implant survival between patients with a
single UPC versus 2 UPCs, (II) comparing infection-free implant survival between patients
with a single UPC treated with antibiotics versus not treated with antibiotics (considered a
contaminant), and (III) reporting on infection-free implant survival for those with a single
Cutibacterium acnes (C. acnes) UPC.

3.2 Patients and Methods
After obtaining ethics approval, we performed a retrospective review of operative notes
and electronic medical records (EMRs) of all consecutive revision THA procedures contained in
our prospective institutional database. We identified 2228 revision THA cases performed at our
tertiary care academic center between January 2006 and April 2019, to allow for a minimum 1year follow-up. Adult patients undergoing a single-stage presumed aseptic revision THA with
intraoperative culture sample(s) taken during the procedure were eligible for inclusion in the
study. Revisions were excluded if (I) PJI was known (including being on chronic antibiotic
suppression) or suspected preoperatively, (II) the revision was part of treatment of PJI
(debridement, antibiotics with implant retention procedure, one-stage or two-stage revision for
PJI), (III) revisions of a hemiarthroplasty, or (IV) if no intraoperative samples were taken for
culture or results were unavailable. Patients lost to follow-up less than 1-year from index study
revision were excluded, unless this was secondary to a death (censored in survival analysis),
subsequent aseptic revision (censored in survival analysis), or recurrent PJI (study endpoint)
within 1-year. All single-stage presumed aseptic revisions meeting inclusion/exclusion criteria
established the base cohort used to determine the prevalence of UPC. Of these, revisions with a
minimum of 1 UPC (organism in broth or solid media) comprised the final study UPC cohort.
A detailed manual review of EMRs was performed to obtain patient, demographic,
laboratory, microbiological, operative, treatment, and outcome data for the UPC study cohort
(Table 3.1 and Table 3.2). There were 9 arthroplasty fellowship trained surgeons performing the
surgeries with the aid of fellows and/or residents during the study period. Routine practice was to
evaluate all failed revisions preoperatively for PJI both clinically and with serum c-reactive
protein (CRP) and erythrocyte sedimentation rate (ESR). However, a joint fluid aspirate was
performed only if these parameters were suspicious for PJI. Intraoperative samples for culture
were taken using swab, fluid aspirate, or tissue samples at the discretion of the treating surgeon.
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The number or type of samples taken was not standardized and varied based on surgeon
preference. The microorganism, solid or broth status, and antibiotic sensitivity of each UPC was
documented. Any cement used during revisions at our institution contains antibiotics (Bone
Cement Antibiotic Simplex P with Tobramycin 1g; Stryker). Postoperatively patients received
either standard 24 to 48-hour prophylactic antibiotics (cefazolin unless patient allergy),
antibiotics until preliminary culture results were negative, or until cultures were negative out to
5-days (if in hospital), based on surgeon preference.
UPC treatment decisions were made by the treating surgeon, often in collaboration with
infectious disease or microbiologist experts. Antibiotic and/or surgical treatment of the UPC was
based on a combination of preoperative, patient, intraoperative/surgical, microorganism, and
postoperative variables, as well as the number of UPCs. However, there was no predefined
protocol for UPC treatment or routine multidisciplinary rounds at our institution.
Infection-related implant failure was defined as the occurrence of infection any time after
the index study revision that required antibiotic treatment or revision surgery for PJI. Prior to
2012 the diagnosis of PJI was based on clinical, laboratory, and intraoperative variables, but not
in a standardized or universally accepted fashion. Since 2012, the diagnosis of PJI at our
institution was made based on the Musculoskeletal Infection Society (MSIS) definition for PJI
criteria and updated versions(11,12). The microorganism(s) grown from cultures of the
subsequent PJI was recorded and compared to the microorganism(s) of the index revision
surgery UPC. All subsequent PJI were treated with surgery and antibiotic therapy, unless
medically unfit for surgery. Any subsequent aseptic revision was documented, with the etiology
and time from index revision surgery noted. Latest EMR clinical follow-up was used as latest
follow-up, unless subsequent PJI, subsequent aseptic revision, or death occurred first (in order of
occurrence).
The secondary aims were achieved by creating cohorts from the UPC study cohort: (I) a 1
UPC versus 2 UPC cohort based on number of UPCs during index revision surgery, (II) a 1
UPC cohort treated with antibiotics versus a 1 UPC cohort not treated with antibiotics
(considered contaminant), and (III) a cohort of patients with a single UPC of C. acnes only.
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3.2.1Statistical Analysis
Statistical analysis was performed using SPSS v26.0 (IBM Inc., Armonk, NY).
Descriptive statistics were used to report on variables and outcomes of interest. Means and
standard deviations (SD), or medians and interquartile ranges (IQR), were used when
appropriate. The prevalence of UPC was calculated. The Kaplan-Meier technique with 95%
confidence intervals (CI) was used to determine the infection-free implant survival at 2 and 5years for UPC study cohort, with subsequent PJI as the endpoint. Patients who died, underwent
subsequent revision, or were lost to follow-up after the 1-year mark were censored. The 2- and 5year Kaplan-Meier survival of the entire UPC cohort was repeated, using subsequent PJI by
same microorganism as the UPC as the endpoint. The 5-year infection-free survival was
calculated for all cohorts of interest, with subsequent PJI as the endpoint. The log-rank test was
used to compare infection-free survival between the cohorts of interest. Categorical data was
compared using the Pearson’s chi-squared test or Fisher’s exact test, when appropriate.
Continuous data was compared using two-sample t tests or Wilcoxon rank-sum tests for
parametric and nonparametric data, respectively. The Shapiro–Wilk test was used to test
normality. Statistical significance was 2-tailed and set at a p-value ≤0.05.

3.3 Results
A flowchart of eligible revisions and number of revisions with UPC is shown in Figure
3.1. After exclusions there were 1336 eligible one-stage aseptic revision THAs. One-hundred
and forty did not have intraoperative samples taken for culture, resulting in a base cohort of 1196
aseptic revisions to determine prevalence of UPC. The prevalence of 1 UPC in presumed
aseptic revision THA was 9.2% (110/1196).
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Figure 3.1. Flowchart of eligible aseptic THA revisions and revisions with UPC.
*Infection related surgeries include 1-stage, 2-stage, and debridement, antibiotics, and implant retention with
modular exchange for periprosthetic joint infection, as well as revisions with known suppressed infection or those
suspected of being infected. †Revisions that had the endpoint of recurrent infection, and those that had subsequent
aseptic revision surgery or died prior to 1-year follow-up were not excluded from survival analysis. THA, total hip
arthroplasty; UPC, unexpected positive intraoperative cultures.

53

In the 110 UPC cohort only 1 revision was lost to follow-up before 1-year for reasons
other than death, a subsequent aseptic revision, or PJI. This patient’s care was transferred closer
to home immediately postoperatively to another city. This resulted in 109 UPC revisions
included in the survival analysis. With time to subsequent PJI, subsequent aseptic revision,
death, or latest clinical follow-up as the endpoint in order of occurrence, the median follow-up
time was 3.3 years (IQR 1.5 to 6.4). Thirty-two revisions with UPC died at a mean of 3.7 years
(SD 2.8). However, 28.1% (9/32) underwent a subsequent aseptic revision or had a PJI-related
failure prior to death and were censored from survival analysis for those reasons. Of the 23
patients that died with no aseptic revision or subsequent PJI, 73.9% (17) died after the 1-year
mark and 26.1% (6) died before the 1 year-mark.
Detailed baseline and operative data for entire UPC study cohort can be seen in Table
3.1. The dominant reason for revision was aseptic loosening, followed by polyethylene wear +/osteolysis, instability, and periprosthetic fracture. Preoperative CRP and ESR were elevated in
18.3% (20) and 19.3% (21) of cases, respectively, and a preoperative aspiration were performed
in 21.1% (23) of cases. Fifty-seven percent (62) of patients underwent a 1-component exchange
during the study revision, and 33.5% (36) underwent modular head and liner exchange only.

Table 3.1. Baseline, demographic, and operative data of study population of 109 UPC
revisions
Variable
Age (years)*
Sex, F/M, n (%)
BMI (kg/m2)*
ASA classification, n (%)
1
2
3
4
Smoking, n (%)
Diabetes, n (%)
Anticoagulation, n (%)
Inflammatory condition, n (%)
Etiology for primary THA, n (%)
Osteoarthritis
Dysplasia
Post-traumatic arthritis
Rheumatoid/inflammatory arthritis
Avascular necrosis
Other

72 (60 to 81)
54/55 (49.5/50.5)
29.2 (24.9 to 33.4)
0 (0)
25 (22.9)
66 (60.6)
18 (16.5)
24 (22.0)
28 (25.7)
13 (11.9)
14 (12.8)
74 (67.9)
9 (8.3)
5 (4.6)
6 (5.5)
6 (5.5)
9 (8.2)
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Reasons for revision, n (%)
Aseptic loosening
Instability
Polyethylene wear +/- osteolysis
Periprosthetic fracture
Adverse metal reaction
Other
Revision number*
History of previous THA revision in study joint, n (%)
Age of prosthesis (years)*
History of PJI in study joint, n (%)
Pre-operative serum CRP > 10mg/L, n (%)
Missing data CRP, n (%)
Pre-operative serum ESR > 30mm/h, n(%)
Missing data ESR, n (%)
Preoperative joint aspirate, n (%)
Type of revision, n (%)
Modular exchange
1-component
2-component
Antibiotic cement used, n (%)

48 (44.0)
16 (14.7)
22 (20.2)
13 (11.9)
8 (7.3)
2 (1.8)
1 (1 to 2)
35 (32.1)
9.0 (2.6 to 17.0)
5 (4.6)
20 (18.3)
6 (5.5)
21 (19.3)
7 (6.4)
23 (21.1)
36 (33.0)
62 (56.9)
11 (10.1)
30 (27.5)

*Values are median (interquartile ranges). UPC, unexpected positive intraoperative cultures; F, female; M,

male; BMI, body mass index; ASA, American society of anesthesiologists; THA, total hip arthroplasty; PJI,
periprosthetic joint infection; CRP, c-reactive protein; ESR, erythrocyte sedimentation rate.

Detailed sampling, microbiological, treatment, and outcome data is shown in Table 3.2.
A median of 4 samples (IQR 3 to 5) were taken per revision case. The most common sample
type was tissue at 63.8% (270). Sixty-three percent (104) of UPC microorganisms were grown in
solid medium, with the remainder grown in broth only. Sixty-eight percent (74) of the cohort had
a single UPC and the remainder had ≥2 UPC. C. acnes was the most frequent microorganism at
37.6% (64). Coagulase-negative Staphylococcus species (CNS) comprised 33.5% (57) of all
microorganisms, the most common being methicillin-resistant Staphylococcus epidermidis
(MRSE) at 12.9% (22) (Table 3.2). Eleven percent (13) of the UPC revisions grew resistant
microorganisms. Thirty-eight percent (41) of patients received antibiotic treatment for their UPC
and the most frequent treatment duration was ≤ 6-weeks (46.3%). However, route and duration
of antibiotic treatment varied (Table 3.2).
Eleven patients were diagnosed with a subsequent PJI at a median of 0.6 years (IQR 0.1
to 2.6). Of these, 6 occurred within 1-year, 4 occurred after the 2-year mark, and none occurred
after 3.5 years. All were treated with surgery and antibiotics, except one palliative patient unfit
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for surgery. Only 4/11 subsequent PJIs grew the same microorganism as the study revision UPC,
1/11 was mixed (subsequent PJI polymicrobial), and 6/11 grew a different microorganism.

Table 3.2. Sampling, microorganism, treatment, and outcome data for study population of
109 UPC revisions
Variable
Number of samples taken in study revision*
Total samples taken, n
Swab samples, n (%)
Fluid samples, n (%)
Tissue samples, n (%)
Total number of UPC’s, n
UPC broth, n (%)
UPC solid, n (%)
1 UPC vs 2 UPC, n (%)
1 UPC
2 UPC
Microorganisms, n (%)
C. acnes
MRSE
Other CNS
MSSE
Streptococcus sp
Micrococcus sp
Enterococcus sp
Corynebacterium sp
MSSA
E. coli
Bacillus sp.
Pseudomonas aeruginosa
Clostridium sp.
Others (7 species single occurrence)
Number of revisions resistant UPC, n (%)
Number revisions polymicrobial UPC, n (%)
Surgical treatment of UPC, n (%)
Antibiotic treatment of UPC, n (%)
Antibiotic route, n (%)
Oral alone
IV alone
Combined IV and oral
Antibiotic duration, n (%)
≤ 6 weeks
≤ 3 months
≤ 6 months
≤ 1 year
Chronic/lifelong suppression
Subsequent aseptic revision, n (%)†
Etiology subsequent aseptic revision, n (%)
Instability

4 (3 to 5)
423
135 (31.9)
18 (4.3)
270 (63.8)
166
62 (37.3)
104 (62.7)
74 (67.9)
35 (32.1)
64 (37.6)
22 (12.9)
19 (11.2)
16 (9.4)
9 (5.3)
8 (4.7)
5 (2.9)
5 (2.9)
4 (2.4)
3 (1.8)
3 (1.8)
3 (1.8)
2 (1.2)
7 (4.1)
13 (11.9)
13 (11.9)
1 (0.9)
41 (37.6)
10 (24.4)
9 (21.9)
22 (53.7)
19 (46.3)
4 (9.8)
7 (17.1)
2 (4.9)
9 (21.9)
9 (8.3)
6 (66.7)
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Aseptic loosening
Time to subsequent aseptic revision (years)‡
Subsequent PJI, n (%)
Time to subsequent PJI (years)*
Subsequent PJI microorganism, n (%)
Same as UPC microorganism
Different than UPC microorganism
Mixed

3 (33.3)
1.7 (1.2)
11 (10.1)
0.6 (0.1 to 2.6)
4 (36.4)
6 (54.5)
1 (9.1)

*Values are median (interquartile ranges). †Subsequent aseptic revision after the study revision, censored
out of survival analysis once occurs as subsequent PJI could be caused by subsequent aseptic revision.
‡Values are mean (standard deviation). UPC, unexpected positive intraoperative cultures; C. acnes,
Cutibacterium acnes; MRSE, methicillin-resistant Staphylococcus epidermidis; CNS, coagulase-negative
Staphylococcus species; MSSE, methicillin-sensitive Staphylococcus epidermidis; sp, species; MSSA,
methicillin-sensitive Staphylococcus aureus; E. coli, Escherichia coli; IV, intravenous; PJI, periprosthetic joint
infection.

The 2- and 5-year infection-free survival for the entire UPC cohort was 93.1% (95% CI
90.5% to 95.7%) and 86.8% (95% CI 82.9% to 90.7%), respectively (Figure 3.2). When
considering only infection-related implant failure caused by the same microorganism as the UPC
as the endpoint, the 2- and 5-year infection free survival for the entire UPC cohort was 95.8%
(95% CI 93.7% to 97.9%) and 94.3% (95% CI 91.7% to 96.9%), respectively (Figure 3.3).
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Figure 3.2. Figure 3.2. Kaplan-Meier 5-year infection-free survival for entire UPC cohort
in presumed aseptic hip revisions.
Vertical spikes are censored data. UPC, unexpected positive intraoperative culture.
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Figure 3. 3. Kaplan-Meier 5-year infection-free survival for entire UPC cohort with
subsequent PJI by the same microorganism as the UPC as the endpoint.
Vertical spikes are censored data. UPC, Unexpected positive intraoperative culture; PJI, periprosthetic joint
infection.

Detailed data for the 1 UPC versus 2 UPC cohorts is shown in Table 3.3. Most variables
were similar between groups (p>0.05), however variability did exist (Table 3.3). C. acnes was
the dominant microorganism in each cohort, however the 2 UPC cohort had a higher proportion
of MRSE and proportions of other microorganisms differed between cohorts (p=0.002) (Table
3.3). The 2 UPC cohort had a higher proportion of resistant microorganisms (p=0.001) and
were more likely to be treated with antibiotics versus the 1UPC cohort (74.3% versus 20.3%)
(p=<0.001). The proportion of broth versus solid UPC was similar between cohorts (p=0.837).
The shorter duration (p=0.096) and higher proportion of oral only antibiotic treatment (p=0.258)
in the 1 UPC cohort was not statistically significant. The 5-year infection-free survival was
similar for the 1 UPC versus 2 UPC cohorts, at 86.4% (95% CI 81.8% to 91.0%) and 88.5%
(95% CI 82.0% to 95%), respectively (p=0.906) (Figure 3.4). Interestingly, 100% (3) of the
subsequent PJIs in the 2 UPC cohort were caused by the same organism as the study revision
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UPC, while only 25% (2) in the 1 UPC cohort were caused by same microorganism as the UPC
(p=0.024).

Table 3.3. Baseline, demographic, operative, microbiological, treatment, and outcome data
for revisions with 1 UPC versus 2 UPC
Variable

1 UPC (n = 74)

2 UPC (n = 35)

P value

Age (years)*
Sex, F/M, n (%)
BMI (kg/m2)*
ASA classification, n (%)
1
2
3
4
Diabetes, n (%)
Inflammatory condition, n (%)
Etiology for primary THA, n (%)
Osteoarthritis
Other
Reasons for revision, n (%)
Aseptic loosening
Instability
Polyethylene wear +/- osteolysis
Periprosthetic fracture
Adverse metal reaction
Other
History of previous THA revision in study
joint, n (%)
Age of prosthesis (years)*
History of PJI in study joint, n (%)
Pre-operative serum CRP > 10mg/L, n (%)
Pre-operative serum ESR > 30mm/h, n (%)
Preoperative joint aspirate, n (%)
Type of revision, n (%)
Modular exchange
1-component
2-component
Number of samples taken in study
revision*
Swab used for culture in revision, n (%)
Fluid used for culture in revision, n (%)
Tissue used for culture in revision, n (%)
UPC broth or solid, n (%)
Broth
Solid
Microorganisms, n (%)
C. acnes
MRSE
MSSE

73.0 (63.8 to 82.0)
39/35 (52.7/47.3)
28.1 (24.8 to 33.7)

69.0 (59 to 80)
15/20 (42.9/57.1)
30.0 (25.1 to 33.2)

0.185a
0.337b
0.664a
0.571c

0
15 (20.3)
47 (63.5)
12 (16.2)
22 (29.7)
12 (16.2)

0
10 (28.6)
19 (54.3)
6 (17.1)
6 (17.1)
2 (5.7)

50 (60.7)
24 (39.3)

24 (68.6)
11 (31.4)

0.160b
0.218c
0.917b

0.940c
32 (43.2)
10 (13.5)
15 (20.3)
10 (13.5)
6 (8.1)
1 (1.4)
20 (27.0)

16 (45.7)
6 (17.1)
7 (20.0)
3 (8.6)
2 (5.7)
1 (2.9)
14 (40.0)

9.0 (2.1 to 17.0)
3 (4.1)
14 (18.9)
16 (21.6)
13 (17.6)

9.0 (3.6 to 22)
2 (5.7)
6 (17.1)
5 (14.3)
10 (28.6)

24 (32.4)
44 (59.5)
6 (8.1)
3.0 (3.0 to 5.0)

12 (34.3)
18 (51.4)
5 (14.3)
4.0 (3.0 to 5.0)

51 (68.9)
9 (12.2)
64 (86.5)

21 (60.0)
7 (20.0)
29 (82.9)

27 (36.5)
47 (63.5)

35 (38.0)
57 (62.0)

0.172b
0.393a
0.655c
0.828b
0.348b
0.189b
0.551b

0.056a
0.359b
0.280b
0.617b
0.837b

0.002c
35 (46.1)
3 (3.9)
7 (9.2)

29 (30.9)
19 (20.2)
9 (9.6)
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Other CNS
Micrococcus sp
MSSA
Streptococcus sp
Enterococcus sp
Corynebacterium sp
Pseudomonas aeruginosa
Others
Number of revisions resistant UPC, n (%)
Antibiotic treatment of UPC, n (%)
Antibiotic route, n (%)
Oral alone
IV alone
Combined IV and oral
Antibiotic duration, n (%)
≤ 6 weeks
≤ 3 months
≤ 6 months
≤ 1 year
Chronic/lifelong suppression
Subsequent aseptic revision, n (%)†
Subsequent PJI, n (%)
Time to subsequent PJI (years)*
Subsequent PJI microorganism, n (%)
Same as UPC microorganism
Different than UPC microorganism
Mixed

12 (15.8)
2 (2.6)
0
5 (6.6)
1 (1.3)
1 (1.3)
0
10 (13.2)
3 (4.1)
15 (20.3)

7 (7.4)
6 (6.4)
4 (4.2)
4 (4.2)
4 (4.2)
4 (4.2)
3 (3.2)
5 (5.3)
10 (28.6)
26 (74.3)

6 (40)
3 (20)
6 (40)

4 (15.4)
6 (23.1)
16 (61.5)

0.001c
0.000b
0.258c

0.096c
11 (73.3)
1 (6.7)
2 (13.3)
0
1 (6.7)
8 (10.8)
8 (10.8)
1.0 (0.1 to 3.1)

8 (30.8)
3 (11.5)
5 (19.2)
2 (7.7)
8 (30.8)
1 (2.9)
3 (8.6)
0.58 (0.1 to 1.1)

1 (12.5)
6 (75.0)
1 (12.5)

3 (100)
0
0

0.267c
1.000c
0.766a
0.024c

*Values are median (interquartile ranges). †Subsequent aseptic revision after the study revision, censored
out of survival analysis once occurs as subsequent PJI could be caused by subsequent aseptic revision.
a
Wilcoxon’s rank-sum test. bPearson’s chi-squared test. cFisher’s exact test. UPC, unexpected positive
intraoperative cultures; F, female; M, male; BMI, body mass index; ASA, American society of
anesthesiologists; THA, total hip arthroplasty; PJI, periprosthetic joint infection; CRP, c-reactive protein; ESR,
erythrocyte sedimentation rate; C. acnes, Cutibacterium acnes; MRSE, methicillin-resistant Staphylococcus
epidermidis; MSSE, methicillin-sensitive Staphylococcus epidermidis; CNS, coagulase-negative
Staphylococcus species; sp, species; MSSA, methicillin-sensitive Staphylococcus aureus; IV, intravenous.
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Figure 3.4. Kaplan-Meier 5-year infection-free survival for the 1 versus 2 UPC cohorts.
Vertical spikes are censored data. UPC, unexpected positive intraoperative culture .
Detailed data for revisions with 1 UPC treated with antibiotics versus not treated with
antibiotics is shown in Table 3.4. Eighty percent (59) of revisions with a single UPC did not
receive antibiotic treatment. The majority of variables were similar between cohorts (p>0.05),
but important differences were noted (Table 3.4). The antibiotic cohort had a higher proportion
of patients with elevated preoperative serum CRP (p=0.003) and ESR (p=0.008). The differences
in type of revision (p=0.068), reasons for revision (p=0.054), and higher proportion of patients
with an inflammatory condition (p=0.059) in the antibiotic treatment were clinically important
but did not reach statistical significance. The proportion of broth versus solid UPC between
cohorts was similar (0.537). Differences in microorganisms were not statistically significant
(p=0.193), however the no antibiotic cohort had a higher proportion of C. acnes. The 5-year
infection free-survival was similar for the 1 UPC antibiotic versus no antibiotic treatment
cohorts, at 84.8% (95% CI 74.8% to 94.8%) and 86.9% (81.8% to 92.0%), respectively
(p=0.706) (Figure 3.5). All of the subsequent PJIs (2/2) in the antibiotic treatment cohort grew
the same microorganism as the study revision UPC (1 same and 1 mixed), however none of the
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subsequent PJIs (0/6) in the no antibiotic cohort were caused by the same microorganism as the
UPC (p=0.036).

Table 3.4. Baseline, demographic, operative, microbiological, treatment, and outcome data
for revisions with 1 UPC treated with antibiotics versus those not treated with antibiotics
Variable

Age (years)*
Sex, F/M, n (%)
BMI (kg/m2)*
ASA classification, n (%)
1
2
3
4
Diabetes, n (%)
Inflammatory condition, n (%)
Etiology for primary THA, n (%)
Osteoarthritis
Other
Reasons for revision, n (%)
Aseptic loosening
Instability
Polyethylene wear +/- osteolysis
Periprosthetic fracture
Adverse metal reaction
Other
History of previous THA revision in study
joint, n (%)
Age of prosthesis (years)*
History of PJI in study joint, n (%)
Pre-operative serum CRP > 10mg/L, n (%)
Pre-operative serum ESR > 30mm/h, n (%)
Preoperative joint aspirate, n (%)
Type of revision, n (%)
Modular exchange
1-component
2-component
Number of samples taken in study
revision*
UPC from swab sample, n (%)
UPC from fluid sample, n (%)
UPC from tissue sample, n (%)
UPC from broth or solid, n (%)
Broth
Solid
Microorganisms, n (%)
C. acnes

Antibiotic treatment

No antibiotic

(n = 15)

treatment (n = 59)

78.0 (63.0 to 85.0)
10/5 (66.7/33.3)
26.7 (25.6 to 33.3)

73.0 (64.0 to 80.0)
29/30 (49.2/50.8)
29.7 (24.6 to 34.3)

0
3 (20.0)
10 (66.7)
2 (13.3)
2 (13.3)
5 (33.3)

0
12 (20.3)
37 (62.7)
10 (16.9)
20 (33.9)
7 (11.9)

9 (60.0)
6 (40.0)

41 (69.5)
18 (30.5)

P value

0.459a
0.225b
0.568a
1.000c

0.205c
0.059c
0.543c

0.054c
7 (46.7)
2 (13.3)
0
5 (33.3)
1 (6.7)
0
2 (13.3)

25 (42.4)
8 (13.6)
15 (25.4)
5 (8.5)
5 (8.5)
1 (1.7)
18 (30.5)

11.0 (3.0 to 19.0)
0
7 (46.7)
7 (46.7)
4 (26.7)

9.0 (2.0 to 17.0)
3 (5.1)
7 (11.9)
9 (15.3)
9 (15.3)

2 (13.3)
13 (86.7)
0
4 (3.0 to 4.0)

22 (37.3)
31 (52.5)
6 (10.2)
3.0 (3.0 to 5.0)

1 (6.7)
1 (6.7)
13 (86.7)

20 (33.9)
1 (1.7)
38 (64.4)

7 (46.7)
8 (53.3)

20 (33.9)
39 (66.1)

0.328c
0.793a
1.000c
0.003c
0.008c
0.458c
0.068c

0.978a
0.205c
0.367c
0.125c
0.537b

0.193c
4 (25.0)

31 (51.7)
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Other CNS
MSSE
Streptococcus sp
MRSE
Micrococcus sp
Others
Number of revisions resistant UPC, n (%)
Subsequent aseptic revision, n (%)
Subsequent PJI, n (%)
Time to subsequent PJI (years)*
Subsequent PJI microorganism, n (%)
Same as UPC microorganism
Different than UPC microorganism
Mixed

5 (31.3)
2 (12.5)
2 (12.5)
1 (6.3)
0
2 (12.5)
1 (6.7)
1 (6.7)
2 (13.3)
1.0 (0.04 to 2.1)

7 (11.7)
5 (8.3)
3 (5.0)
2 (3.3)
2 (3.3)
10 (16.7)
2 (3.4)
7 (11.9)
6 (10.2)
1.3 (0.1 to 3.3)

1 (50.0)
0
1 (50.0)

0
6 (100)
0

0.499c
1.000c
0.660c
0.429a
0.036c

*Values are median (interquartile ranges). †Subsequent aseptic revision after the study revision, censored

out of survival analysis once occurs as subsequent PJI could be caused by subsequent aseptic revision.
a
Wilcoxon’s rank-sum test. bPearson’s chi-squared test. cFisher’s exact test. UPC, unexpected positive
intraoperative cultures; F, female; M, male; BMI, body mass index; ASA, American society of
anesthesiologists; THA, total hip arthroplasty; PJI, periprosthetic joint infection; CRP, c-reactive protein; ESR,
erythrocyte sedimentation rate; C. acnes, Cutibacterium acnes; CNS, coagulase-negative Staphylococcus
species; MSSE, methicillin-sensitive Staphylococcus epidermidis; sp, species; MRSE, methicillin-resistant
Staphylococcus epidermidis.

Figure 3.5. Kaplan-Meier 5-year infection-free survival for the 1 UPC cohort treated with
antibiotics (yes) versus not treated with antibiotics (no).
Vertical spikes are censored data. UPC, unexpected positive intraoperative culture.
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Detailed data for the 1 UPC cohort with C. acnes is shown is Table 3.5. The 5-year
infection-free survival was 83.3% (95% CI 76.3% to 90.3%). Only 4/35 patients were treated
with antibiotics and all for ≤6 weeks duration. However, 4/5 of the subsequent PJIs were caused
by different microorganisms than the UPC and only 1/5 of the subsequent PJIs grew C. acnes
(polymicrobial).

Table 3.5. Baseline, demographic, operative, microbiological, treatment, and outcome data
for revisions with a single UPC of C. acnes (n = 35)
Variable
Age (years)*
Sex, F/M, n (%)
BMI (kg/m2)*
ASA classification, n (%)
1
2
3
4
Diabetes, n (%)
Inflammatory condition, n (%)
Etiology for primary THA, n (%)
Osteoarthritis
Other
Reasons for revision, n (%)
Aseptic loosening
Instability
Polyethylene wear +/- osteolysis
Periprosthetic fracture
Adverse metal reaction
Other
History of previous THA revision in study joint, n (%)
Age of prosthesis (years)*
History of PJI in study joint, n (%)
Pre-operative serum CRP > 10mg/L, n (%)
Pre-operative serum ESR > 30mm/h, n (%)
Preoperative joint aspirate, n (%)
Type of revision, n (%)
Modular exchange
1-component
2-component
Number of samples taken in study revision*
UPC from a swab sample, n (%)
UPC from a tissue sample, n (%)
UPC broth, n (%)
UPC solid, n (%)
Number of revisions resistant UPC, n (%)

69.0 (58.0 to 79.0)
17/18 (48.6/51.4)
28.4 (24.6 to 34.4)
0
8 (22.9)
21 (60.0)
6 (17.1)
12 (34.3)
4 (11.4)
23 (65.7)
12 (34.3)
17 (48.6)
4 (11.4)
5 (14.3)
5 (14.3)
4 (11.4)
0
11 (31.4)
9.0 (2.0 to 14.0)
2 (5.7)
5 (14.3)
7 (20)
7 (20.0)
9 (25.7)
22 (62.9)
4 (11.4)
3.0 (3.0 to 5.0)
10 (28.6)
25 (71.4)
13 (37.1)
22 (62.9)
0
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Antibiotic treatment of UPC, n (%)
Antibiotic route, n (%)
Oral alone
IV alone
Combined IV and oral
Antibiotic duration, n (%)
≤ 6 weeks
≤ 3 months
≤ 6 months
≤ 1 year
Chronic/lifelong suppression
Subsequent aseptic revision, n (%)†
Subsequent PJI, n (%)
Time to subsequent PJI (years)*
Subsequent PJI microorganism, n (%)
Same as UPC microorganism
Different than UPC microorganism
Mixed

4 (11.4)
3 (75.0)
1 (25.0)
0
4 (100.0)
0
0
0
0
3 (8.6)
5 (14.3)
0.1 (0.5 to 2.9)
0
4 (80.0)
1 (20.0)

*Values are median (interquartile ranges).†Subsequent aseptic revision after the study revision,
censored out of survival analysis once occurs as subsequent PJI could be caused by subsequent aseptic
revision. UPC, unexpected positive intraoperative cultures; C. acnes, Cutibacterium acnes; F, female; M,
male; BMI, body mass index; ASA, American Society of Anesthesiologists classification; THA, total hip
arthroplasty; PJI, periprosthetic joint infection; CRP, c-reactive protein; ESR, erythrocyte sedimentation
rate; IV, intravenous.

3.4 Discussion
The prevalence, clinical significance, and outcomes of UPC in presumed aseptic revision
THA are unclear. Our aims were to report on the prevalence and infection-free survival in this
patient population, as well as other clinical cohorts of interest. To our knowledge, this is the
largest series of UPC in presumed aseptic revision THA in the literature.
We demonstrated that the prevalence of UPC in presumed aseptic revision THA was
9.2%, similar to that of 10.5% reported by a recent review of UPC in revision total knee (TKA)
and THA(17). However, UPC was twice more common in THA than TKA and there was
considerable variability (4-38%) between studies due to differences in preoperative evaluation
protocols, aseptic revision cohort baseline data, sample size, follow-up, sampling and laboratory
techniques, and definitions of UPC or PJI(17). We included broth only UPC because the
specificity of these cultures have been shown to be high(23), and other studies have as
well(18,20). Although studies including single UPCs tend report a higher incidence(19,20,24–
27), the reported incidence varies when considering only 2 UPC as well(14,18,21,28–30).
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Jacobs et al.(18) reported a 12.1% (26/214) incidence of PJI diagnosed by 2 UPC by the same
microorganism in their THA cohort, excluding a single UPC as a contaminant or false-positive.
In our institution the prevalence of UPC with 2 UPC was only 3.0% (36). C. acnes and CNS
were the most common microorganisms, supporting the indolent nature of microorganisms
common to UPC in the literature(17,18,20). Staphylococcus epidermidis and CNS are the most
common microorganisms identified in the majority of early studies(14,19,20,28,31), however, C.
acnes was also reported as the most common microorganism in a recent study with extended
anaerobic incubation times(18). Our increased detection of C. acnes and may be due to the
extended anerobic incubation time of 10-14 days for the majority of the study period and UPC
revisions in our study, which has been shown to increase the detection of C. acnes
substantially(32). Although infrequent, virulent and antibiotic resistant microorganisms did
occur(17,20).
The 2- and 5-year infection-free survival for the entire UPC cohort was 93.1% (95% CI
90.5% to 95.7%) and 86.8% (95% CI 82.9% to 90.7%), respectively. We report on infection-free
survival in hips separate from knees because the prognosis for these two cohorts has recently
been show to differ(18). Additionally, we felt that reporting out to 5-years was important given
the low virulence microorganisms common to UPC. No failure due to PJI were encountered after
3.5 years. The results of our large cohort are encouraging and consistent with a majority of the
literature(17,18,20). In hips, Jacobs et al(18) found that the 2 UPC PJI cohort had similar
infection free survival at 2-years as the aseptic cohort, however there were only 26 revisions in
the UPC cohort. The majority of studies reporting 95-100% infection-free survival tended to
have short follow-up or use advanced techniques such as implant sonication or molecular
technology(14,27,31,33), both of which do not apply to our study. Even more encouraging is that
when only considering infection-related failure caused by the same microorganism as the UPC,
the 2- and 5-year infection-free survival for the entire UPC cohort was 95.8% (95% CI 93.7% to
97.9%) and 94.3% (95% CI 91.7% to 96.9%), respectively. Subsequent PJIs caused by different
microorganisms likely represent a new infection independent of the UPCs, however it is possible
that these microorganisms were present during the study revision but missed due to sensitivity
limitations of cultures to identify microorganisms in PJI(34).
The infection-free survival between the 1 UPC and 2 UPC cohorts were similar in our
study. However, this finding must be treated with caution. The 2 UPC had more patients treated
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with antibiotics, differences in type of microorganisms, a higher proportion of resistant
microorganisms, and a higher proportion on lifelong antibiotic suppression compared to the 1
UPC cohort. Saleh et al.(20) found that patients with a single UPC that did not meet institutional
criteria for antibiotic treatment had lower rates of infection than those treated with antibiotics,
whether the antibiotic cohort was MSIS criteria positive or not. Although the survival of 2 UPC
is favorable in the literature(17–19), unacceptably high failure rates have been reported in this
cohort(31,33). Our results suggest that the 2 UPC cohort is much more likely than the 1 UPC
cohort to fail from ongoing or recurrent infection with the same microorganisms as the UPC
(100% versus 25%). These findings agree with that the majority of the literature (17,20), but are
not universal (18).
Nearly 80% (59) of patients with 1 UPC in our study did not receive antibiotic treatment
and had similar-infection free survival as the 1UPC cohort treated with antibiotics. Similarly,
these results must be interpreted with caution due to differences between cohorts and an
important selection bias for those treated with antibiotics. We found that no subsequent PJI in the
no antibiotic treatment cohort was caused by the same microorganism as the UPC, while all
subsequent PJIs in the antibiotic cohort grew the same UPC microorganism. In the revisions with
a single C. acnes UPC only 4/35 patients were treated with a short course of antibiotics and the
5-year infection-free survival was 83.3% (95% CI 76.3% to 90.3%). However, 4/5 of the
subsequent PJIs were caused by different microorganisms than the UPC.
There is considerable controversy regarding the clinical significance of a single UPC.
Several authors have suggested that in that the absence of other signs of infection single UPCs
are likely contaminants and do not require treatment(14,19,26), a notion supported by the MSIS
definition of PJI(11). C. acnes was a common single UPC in these studies and was specifically
reported on by Dramis et al.(26). However, Saleh et al.(20) showed that even a single UPC with
a high virulence microorganism not meeting MSIS criteria for PJI may truly be an infection and
require antibiotic treatment. Revisions with a single UPC in our study had an extremely low risk
of developing a recurrent infection with the same microorganism and those not treated with
antibiotics had no recurrent infections by the UPC microorganism. Our results suggest that a
single UPC without signs of infection is likely a contaminant and can be observed clinically
without antibiotic treatment.
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The current study has limitations. This is a single high-volume academic center and
results may not be generalizable. However, the multiple surgeons included may help improve the
generalizability of the results and most of our results are consistent with the literature. The
retrospective design of this is subject to associated biases. There was no standardized
preoperative PJI screening protocol, however all revisions were evaluated both clinically and
with serum CRP and ESR. An aspirate was ordered selectively based suspicion for PJI, thus
MSIS criteria could not be retrospectively applied. Consistent with the majority of UPC
literature, the type and number of samples taken during revision surgery for culture was not
standardized, both of which have been shown to be important for detecting microorganisms and
PJI(24,35,36). Additionally, the lack of a standardized UPC treatment protocol introduced
important selection biases. Lastly, our study was underpowered to detect differences between
cohorts for secondary outcomes of interest. However, the UPC literature is limited and this study
represents the largest series of UPC in presumed aseptic THA. Additionally, the inclusion of
single UPC provides data a common and clinically controversial problem.
In conclusion, the prevalence of UPC in presumed aseptic revision THA was 9.2% and
the infection-free survival at 2 and 5-years is encouraging. The infection-free implant survival
when only considering PJI by the same UPC microorganism is excellent. Although we did not
find a difference in infection-free implant survival between cohorts of interest, this must be
interpreted with caution. Patients with 2 UPC or a single UPC that was deemed to require
antibiotic treatment were more likely to have recurrent infection with the same microorganism as
the UPC. Patients with a single UPC are unlikely to have recurrent infection by the same
microorganism as the UPC and no patient with a single UPC not treated with antibiotics had an
infection with the same microorganism. Thus, patients with a single UPC and no other signs of
infection can be considered contaminants, and do not require antibiotic treatment.
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Chapter 4

4.

The Prevalence and Outcomes of Unexpected Positive

Intraoperative Cultures in Presumed Aseptic Revision Knee
Arthroplasty

4.1 Introduction
Total knee arthroplasty (TKA) is a highly successful and cost-effective treatment for endstage arthritis(1). Currently, over 1 million TKA are performed in North America annually(2,3),
and these numbers are expected to increased markedly(2,4). At the 10-year mark, up to 12% of
primary TKA require revision surgery(5), and the number of revisions is also projected to
increase substantially(4).
Periprosthetic joint infection (PJI) occurs at a rate of approximately 2% for primary TKA
and is a leading cause for revision(6–8). PJI is associated with enormous financial cost and
morbidity, and the rate of this dreaded complication has remained constant over time(6,7,9,10).
Despite great scientific effort there remains no perfect test to diagnose PJI in TKA(11–13), and a
proportion of presumed aseptic failures may be undiagnosed PJI(14–16). Consequently,
unexpected positive intraoperative cultures (UPC) in presumed aseptic revisions occur and can
be expected to remain a problem. UPCs are clinically challenging because the surgeon becomes
aware of the UPC after the presumed aseptic revision surgery, and the surgical management of
aseptic failure differs significantly compared to PJI-related failure.
The prevalence of UPC in presumed aseptic revision TKA remains unclear (4-38%), as
does the optimal treatment and clinical consequence in terms of infection-free survival(14,17–
21). There is debate regarding the clinical significance of PJI diagnosed by UPC, and the
significance of a single UPC in presumed aseptic revision is even more uncertain(17–19,21,22).
The literature on UPC in revision TKA is inadequate and larger studies are needed(21).
Our primary aim was to determine the prevalence of UPC in presumed aseptic revision
TKA and the infection-free implant survival for this cohort. Secondarily, we aimed to (I)
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compare the infection-free implant survival between patients with 1 versus 2 UPCs and (II)
compare the infection-free implant survival between patients treated with antibiotics versus not
treated with antibiotics (considered a contaminant).

4.2 Patients and Methods
Our prospectively maintained institutional database was used to identify all 1795
consecutive revision TKA cases performed at our academic tertiary care center between January
2006 and April 2019. A retrospective review of operative notes and electronic medical records
(EMRs) was performed to apply study inclusion and exclusion criteria. Adult patients that
underwent presumed aseptic single-stage revision TKA with intraoperative culture samples(s)
taken were eligible for inclusion. Revisions with no intraoperative samples taken for culture were
excluded, as were revisions of patellofemoral or unicompartmental replacements. Patients on
chronic antibiotic suppression for PJI were excluded. Revisions were excluded if PJI was known
or suspected preoperatively, as were revisions that were part of treatment for PJI (debridement,
antibiotics with retention of nonmodular implants, one-stage or two-stage revision for PJI).
Patients lost to follow-up less than 1-year from the index study revision were excluded, unless
this was secondary to a subsequent aseptic revision (censored in survival analysis) or recurrent
PJI (study endpoint). The base cohort to determine the prevalence of UPC was comprised of all
single-stage presumed aseptic revisions meeting inclusion/exclusion criteria. Of these, the final
UPC study cohort was comprised of revisions with a minimum of 1 UPC (organism in broth or
solid medium). Ethics approval was obtained from our institutional REB.
For the UPC study cohort a manual review of EMRs was performed to obtain patient,
demographic, laboratory, microbiological, surgical, treatment, and outcome data (Table 4.1 and
Table 4.2). Surgeries were performed by 9 fellowship trained arthroplasty surgeons with the
assistance of residents and/or fellows. All revisions were evaluated preoperatively for PJI both
clinically and with serum c-reactive protein (CRP) and erythrocyte sedimentation rate (ESR).
However, a joint fluid aspirate was only obtained selectively when these parameters were
suspicious of PJI. The number or type (swab, fluid aspirate, tissue) of intraoperative samples
taken for culture was at the discretion of the treating surgeon and varied based on the preference
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of the treating surgeon. For each UPC the microorganism, antibiotic sensitivities, and broth or
solid medium status was documented.
All cement used in revisions contained antibiotics (Bone Cement Antibiotic Simplex P
with Tobramycin 1g; Stryker). Postoperative antibiotic prophylaxis (1-2g cefazolin unless patient
allergy) varied based on surgeon preference including standard 24-48 hours, antibiotics until
preliminary culture results were negative, or antibiotics until 5-day culture results were negative
(if in hospital).
There was no predefined treatment protocol for UPC at our institution, nor is there
routine interdisciplinary rounds. The surgeon based the need for antibiotic and/or surgical
treatment of UPC based on a combination of preoperative, patient, intraoperative/surgical,
microorganism, and postoperative factors, as well as the number of UPCs. Infectious disease
experts were often consulted to aid with treatment decisions.
Infection-related implant failure was defined as the occurrence of infection that required
antibiotic treatment or revision surgery for PJI at any time after the index study revision. Since
the year 2012, the diagnosis of PJI at our institution was made according to the Musculoskeletal
Infection Society’s (MSIS) definition for PJI criteria and updated versions(11,12). Prior to 2012
PJI was diagnosed based on clinical, laboratory, and intraoperative variables, but not in a
universally accepted or standardized manner. The causative microorganism(s) of any subsequent
PJI-related failure was recorded and compared to the microorganism(s) of the index revision
surgery UPC. All subsequent PJI was treated with surgery and antibiotics. If a subsequent aseptic
revision occurred it was documented, as well as the etiology and time from index study revision.
Latest EMR clinical follow-up was used as latest follow-up, unless subsequent PJI, subsequent
aseptic revision, or death occurred first (in order of occurrence).
Secondary study aims were accomplished by creating cohorts from the UPC study cohort:
(I) a 1 UPC versus 2 UPC cohort based on number of UPCs during index revision surgery, and
(II) an UPC treated with antibiotics cohort versus not treated with antibiotics cohort (considered
contaminant).
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4.2.1Statistical Analysis.
Statistical analysis was performed using SPSS v26.0 (IBM Inc., Armonk, NY). The
prevalence of UPC was calculated. Variables and outcomes of interest were reported on using
descriptive statistics. Medians and interquartile ranges (IQR) or means and standard deviations
(SD) were used, when appropriate. The Kaplan-Meier technique with 95% confidence intervals
(CI) was used to determine the infection-free implant survival at 2 and 5-years for UPC study
cohort, with subsequent PJI as the endpoint. Patients who died, underwent subsequent aseptic
revision, or were lost to follow-up after the 1-year mark were censored. The 5-year KaplanMeier survival of the entire UPC cohort was repeated using subsequent PJI caused by same
microorganism as the UPC as the endpoint. The 5-year infection-free survival was also
calculated for all cohorts of interest, with subsequent PJI as the endpoint. Log-rank tests were
used to compare infection-free survival between cohorts of interest. Continuous data was
compared between cohorts using Mann-Whitney U tests or two-sample t tests for nonparametric
and parametric data, respectively. The Shapiro–Wilk test was used to test normality. Categorical
data was compared between cohorts using the Pearson’s chi-squared test or Fisher’s exact test,
when appropriate. Statistical significance was 2-tailed and set at a p-value ≤0.05.

4.3 Results
After exclusions, the base cohort was comprised of 775 single-stage presumed aseptic
revisions with intraoperative cultures taken (Figure 4.1). The prevalence of 1 UPC in presumed
aseptic revision TKA was 9.8% (76/775). No revisions were lost to follow-up before 1-year for
reasons other than subsequent aseptic revision or PJI. The median follow-up time was 3.6 years
(IQR 2.0 to 6.2) with time to subsequent PJI, subsequent aseptic revision, death, or latest clinical
follow-up as the endpoint (in order of occurrence). Ten revisions with UPC died at a mean of 5.3
years (SD 2.5), none before the 1-year mark.
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Figure 4.1. Flowchart of eligible aseptic TKA revisions and revisions with UPC.
*Infection related surgeries include 1-stage, 2-stage, and debridement, antibiotics, and implant retention with
modular exchange for periprosthetic joint infection, as well as revisions with known suppressed infection or those
suspected of being infected. †Revisions that had the endpoint of subsequent infection-related implant failure, or
those that had subsequent aseptic revision surgery prior to 1-year follow-up were not excluded from survival
analysis. TKA, total knee arthroplasty; UPC, unexpected positive intraoperative cultures.

Baseline and operative data for entire UPC study cohort can be seen in Table 4.1. Aseptic
loosening and instability were the dominant modes of failure. Preoperative serum CRP and ESR
were elevated in 11.8% (9) and 9.2% (7) of revisions. Thirty-two percent (24) of revisions had a
preoperative joint aspirate performed. The majority (73.7%) of patients underwent a two-
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component revision of the femur and tibia. Microbiological, treatment, and outcome data is
shown in Table 4.2. Fifty-five percent (162) of operative samples for culture were tissue and a
median 4 samples (IQR 3 to 5) were taken per revision. Nearly 82% (62) of the cohort had a
single UPC and 51.6 % (48) of UPCs were grown in broth only. Cutibacterium acnes (C. acnes)
was the most common microorganism (32.4%) identified followed by methicillin-sensitive
Staphylococcus epidermidis (MSSE) (21.6%), however, coagulase-negative Staphylococcus
(CNS) species comprised 45.1% of all microorganisms (Table 4.2). Only 35.5% (27) of patients
received antibiotic treatment for their UPC, the vast majority (92.6%) for a duration of ≤6 weeks,
though route of antibiotics varied (Table 4.2).

Table 4.1. Baseline, demographic, and operative data of study population of 76 UPC
revisions
Variable
Age (years)*
Sex, F/M, n (%)
BMI (kg/m2)†
ASA classification, n (%)
1
2
3
4
Smoking, n (%)
Diabetes, n (%)
Anticoagulation, n (%)
Inflammatory condition, n (%)
Etiology for primary TKA, n (%)
Osteoarthritis
Rheumatoid/inflammatory arthritis
Avascular necrosis/SONK
Post-traumatic arthritis
Other
Reasons for revision, n (%)
Aseptic loosening
Instability
Arthrofibrosis
Polyethylene wear +/- osteolysis
Patellar problem
Pain no known source
Periprosthetic fracture
Pain component malposition
Revision number†
History of prior TKA revision in study joint, n (%)
Age of prosthesis (years)†
History of PJI in study joint, n (%)

69.3 (9.0)
47/29 (61.8/38.2)
33.6 (28.6 to 37.8)
0 (0)
18 (23.7)
56 (73.7)
2 (2.6)
10 (13.2)
18 (23.7)
7 (9.2)
10 (13.2)
66 (86.8)
5 (6.6)
2 (2.6)
2 (2.6)
1 (1.3)
34 (44.7)
22 (28.9)
6 (7.9)
4 (5.3)
4 (5.3)
4 (5.3)
1 (1.3)
1 (1.3)
1.0 (1.0 to 1.0)
11 (14.5)
8.9 (3.3 to 14.6)
2 (2.6)

79

Preoperative serum CRP > 10mg/L, n (%)
Missing data CRP, n (%)
Preoperative serum ESR > 30mm/h. n (%)
Missing data ESR, n (%)
Preoperative joint aspirate, n (%)
Type of revision, n (%)
Patella
Modular exchange
1-component
2-component
Antibiotic cement used, n (%)
Cemented stems used, n (%)

9 (11.8)
1 (1.3)
7 (9.2)
1 (1.3)
24 (31.6)
4 (5.3)
8 (10.5)
8 (10.5)
56 (73.7)
70 (92.1)
9 (11.8)

*Values are mean (standard deviation). †Values are median (interquartile range). UPC, unexpected positive
intraoperative culture; F, female; M, male; BMI, body mass index; ASA, American society of
anesthesiologists; TKA, total knee arthroplasty; SONK, spontaneous osteonecrosis of the knee; PJI,
periprosthetic joint infection; CRP, c-reactive protein; ESR, erythrocyte sedimentation rate.

Table 4.2. Sampling, microorganism, treatment, and outcome data for study population of
76 UPC revisions
Variable
Number of samples taken in study revision*
Total samples taken, n
Swab samples, n (%)
Fluid samples, n (%)
Tissue samples, n (%)
Total number of UPC’s, n
UPC broth, n (%)
UPC solid, n (%)
1 UPC vs 2 UPC, n (%)
1 UPC
2 UPC
Microorganisms, n (%)
C. acnes
Other CNS
MSSE
MRSE
Streptococcus sp
Enterococcus sp
Bacillus sp.
Corynebacterium sp
Others (6 species)
Number of revisions resistant UPC, n (%)
Number revisions polymicrobial UPC, n (%)
Surgical treatment of UPC, n (%)
Antibiotic treatment of UPC, n (%)
Antibiotic route, n (%)
Oral alone
IV alone

4 (3.0 to 5.0)
295
113 (38.3)
20 (6.8)
162 (54.9)
93
48 (51.6)
45 (48.4)
62 (81.6)
14 (18.4)
33 (32.4)
23 (22.5)
22 (21.6)
1 (1.0)
8 (7.8)
4 (3.9)
3 (2.9)
2 (2.0)
6 (5.9)
4 (5.3)
12 (15.8)
1 (1.3)
27 (35.5)
12 (44.4)
9 (33.3)
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Combined IV and oral
Antibiotic duration, n (%)
≤ 6 weeks
≤ 3 months
≤ 6 months
Subsequent aseptic revision, n (%)†
Etiology subsequent aseptic revision, n (%)
Instability
Aseptic loosening
Periprosthetic fracture
Avascular necrosis patella
Time to subsequent aseptic revision (years)‡
Subsequent PJI, n (%)
Subsequent PJI microorganism, n (%)
Same as UPC microorganism
Mixed
Different than UPC microorganism

6 (22.2)
25 (92.6)
1 (3.7)
1 (3.7)
4 (5.3)
1 (25.0)
1 (25.0)
1 (25.0)
1 (25.0)
3.5 (2.7)
3 (3.9)
0 (0)
1 (33.3)
2 (66.7)

*Values are median (interquartile ranges). †Subsequent aseptic revision after the study revision, censored
out of survival analysis once occurs as subsequent PJI could be caused by subsequent aseptic revision.
‡Values are mean (standard deviation). UPC, unexpected positive intraoperative culture; C. acnes,
Cutibacterium acnes; CNS, coagulase-negative Staphylococcus species; MSSE, methicillin-sensitive
Staphylococcus epidermidis; MRSE, methicillin-resistant Staphylococcus epidermidis; sp, species; IV,
intravenous; PJI, periprosthetic joint infection.

Three patients were diagnosed with a subsequent PJI at a mean of 1.1 years (SD 1.4)
(Table 4.3). Of note, 2/3 of subsequent PJIs were caused by a different microorganism than the
study revision UPC, and 1/3 was polymicrobial with one causative microorganism the same as
the study revision UPC (Table 4.2 and Table 4.3). The 2- and 5-year infection-free survival for
the entire UPC cohort was 97.4% (95% CI 95.6% to 99.2%) and 95.3% (92.6% to 98.0%),
respectively (Figure 4.2). When considering only infection-related implant failure caused by the
same microorganism as the UPC as the endpoint, the 5-year infection-free survival for the entire
UPC cohort was 98.7% (95% CI 97.4% to 100%) (Figure 4.3).
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Table 4.3. Patient, operative, microorganism, and treatment data for revisions with an
UPC that had a subsequent PJI-related implant failure (n = 3)
Variable
Age (years)
Sex
BMI (kg/m2)
Etiology for primary TKA
Revision number
Age of prosthesis (years)
Reason for revision
History of PJI in study joint
Preoperative serum CRP (mg/L)
Preoperative serum ESR (mm/h)
Preoperative joint aspirate
Type of revision
Number of UPC’s
UPC solid or broth
UPC microorganism(s)
Surgical treatment UPC
Antibiotic treatment UPC
Time to subsequent PJI (years)
Microorganism(s) subsequent PJI

Case 1

Case 2

Case 3

73
Female
30.7
Osteoarthritis
1
8
Aseptic loosening
No
0.3
9
No
2-component
1
Solid
C. acnes
No
6 weeks oral
0.2
C. acnes + Proteus
Mirabilis

68
Female
55.8
Osteoarthritis
1
17
Aseptic loosening
No
8.5
13
Yes
2-component
1
Broth
Staph warneri
No
6 weeks oral
0.3
MSSA

90
Male
27.1
Osteoarthritis
1
4
Instability
No
1.2
7
No
Modular exchange
1
Broth
MRSE
No
6 weeks oral
2.7
Culture-negative

UPC, unexpected positive intraoperative culture; PJI, periprosthetic joint infection; BMI, body mass index;
TKA, total knee arthroplasty; CRP, c-reactive protein; ESR, erythrocyte sedimentation rate; C. acnes,
Cutibacterium acnes; Staph, Staphylococcus; MRSE, methicillin-resistant Staphylococcus epidermidis; MSSA,
methicillin-sensitive Staphylococcus aureus.
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Figure 4.2. Kaplan-Meier 5-year infection-free survival for entire UPC cohort in presumed
aseptic knee revisions.
Vertical spikes are censored data. UPC, unexpected positive intraoperative culture.
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Figure 4.3. Kaplan-Meier 5-year infection-free survival for entire UPC cohort with
subsequent PJI by the same microorganism as the UPC as the endpoint.
Vertical spikes are censored data. UPC, unexpected positive intraoperative culture; PJI, periprosthetic joint
infection.

Detailed data for the 1 UPC versus 2 UPC cohorts is shown in Table 4.4. The vast
majority of variables showed no statistical difference between groups (p >0.05), however there
was variability (Table 4.4). C. acnes was the most common microorganism in the single UPC
cohort whereas MSSE was the most common in the 2 UPC cohort, and the proportions of
microorganisms differed between cohorts (p =0.029). The 2 UPC cohort was more likely to
receive antibiotic treatment of the UPC (64.3% versus 29.0%, p =0.027). Although there was
variability in the route (p =0.123) and duration (p =0.103) of antibiotic treatment between
cohorts, these differences were not statistically significant. All 3 of the subsequent PJIs were in
the single UPC cohort (p =1.000). However, the 5-year infection-free survival was similar for the
1 UPC versus 2 UPC cohorts, at 94.3% (95% CI 91.0% to 97.6%) and 100%, respectively (p
=0.416) (Figure 4.4).
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Table 4.4. Baseline, demographic, operative, microbiological, treatment, and outcome data
for revisions with 1 UPC versus 2 UPC
Variable

1 UPC (n = 62)

2 UPC (n = 14)

P value

Age (years)*
Sex, F/M, n (%)
BMI (kg/m2)†
ASA classification, n (%)
1
2
3
4
Diabetes, n (%)
Inflammatory condition, n (%)
Etiology for primary TKA, n (%)
Osteoarthritis
Other
Reasons for revision, n (%)
Aseptic loosening
Instability
Arthrofibrosis
Polyethylene wear +/- osteolysis
Patellar problem
Pain no known source
Periprosthetic fracture
Pain component malposition
History of prior TKA revision in study joint
n (%)
Age of prosthesis (years)†
History of PJI in study joint, n (%)
Pre-operative serum CRP > 10mg/L, n (%)
Pre-operative serum ESR > 30mm/h, n (%)
Preoperative joint aspirate, n (%)
Type of revision, n (%)
Patella
Modular exchange
1-component
2-component
Number of samples taken in study
revision†
Swab used for culture in revision, n (%)
Fluid used for culture in revision, n (%)
Tissue used for culture in revision, n (%)
UPC broth or solid, n (%)
Broth
Solid
Microorganisms, n (%)
C. acnes
Other CNS
MSSE
MRSE
Streptococcus sp

69.2 (8.8)
36/26 (58.1/41.9)
33.3 (28.5 to 38.0)

69.6 (9.8)
11/3 (78.6/21.4)
34.7 (31.3 to 38.2)

0.872a
0.154b
0.445c
0.294d

0 (0)
16 (25.8)
45 (72.6)
1 (1.6)
15 (24.2)
9 (14.5)

0 (0)
2 (14.3)
11 (78.6)
1 (7.1)
3 (21.4)
1 (7.1)

53 (85.5)
9 (14.5)

13 (92.9)
1 (7.1)

1.000d
0.678d
0.678d

0.926d
29 (46.8)
17 (27.4)
5 (8.1)
3 (4.8)
3 (4.8)
3 (4.8)
1 (1.6)
1 (1.6)
10 (16.1)

5 (35.7)
5 (35.7)
1 (7.1)
1 (7.1)
1 (7.1)
1 (7.1)
0 (0)
0 (0)
1 (7.1)

8.7 (3.1 to 13.9)
2 (3.2)
8 (12.9)
6 (9.7)
20 (32.3)

12.0 (5.5 to 16.3)
0 (0)
1 (7.1)
1 (7.1)
4 (28.6)

2 (3.2)
7 (11.3)
7 (11.3)
46 (74.2)
4.0 (3.0 to 5.0)

2 (14.3)
1 (7.1)
1 (7.1)
10 (71.4)
4.0 (3.0 to 5.0)

43 (69.4)
16 (25.8)
50 (80.6)

11 (78.6)
4 (28.6)
9 (64.3)

30 (48.4)
32 (51.6)

18 (58.1)
13 (41.9)

0.678d
0.366c
1.000d
1.000d
1.000d
1.000d
0.391d

0.217c
0.745d
1.000d
0.284d
0.379b

0.029d
24 (36.9)
16 (24.6)
8 (12.3)
1 (1.5)
6 (9.2)

9 (24.3)
7 (18.9)
14 (37.8)
0 (0)
2 (5.4)
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Enterococcus sp
Others
Number of revisions resistant UPC, n (%)
Antibiotic treatment of UPC, n (%)
Antibiotic route, n (%)
Oral alone
IV alone
Combined IV and oral
Antibiotic duration, n (%)
≤ 6 weeks
≤ 3 months
≤ 6 months
Subsequent aseptic revision, n (%)‡
Subsequent PJI, n (%)
Subsequent PJI microorganism, n (%)
Same as UPC microorganism
Mixed
Different than UPC microorganism

1 (1.5)
9 (13.8)
2 (3.2)
18 (29.0)

3 (8.1)
2 (5.4)
2 (14.3)
9 (64.3)

10 (55.6)
6 (33.3)
2 (11.1)

2 (22.2)
3 (33.3)
4 (44.4)

18 (100.0)
0 (0)
0 (0)
2 (3.2)
3 (4.8%)

7 (77.8)
1 (11.1)
1 (11.1)
2 (14.3)
0 (0)

0 (0)
1 (33.3)
2 (66.7)

Not applicable
Not applicable
Not applicable

0.152d
0.027d
0.123d

0.103d

0.152d
1.000d
Not applicable

*Values are mean (standard deviation). †Values are median (interquartile ranges). ‡Subsequent aseptic
revision after the study revision, censored out of survival analysis once occurs as subsequent PJI could be
caused by subsequent aseptic revision. aTwo-sample t test. bPearson’s chi-squared test. cMann-Whitney U
test. dFisher’s exact test. UPC, unexpected positive intraoperative culture; F, female; M, male; BMI, body
mass index; ASA, American society of anesthesiologists; TKA, total knee arthroplasty; PJI, periprosthetic
joint infection; CRP, c-reactive protein; ESR, erythrocyte sedimentation rate; C. acnes, Cutibacterium acnes;
CNS, coagulase-negative Staphylococcus species; MSSE, methicillin-sensitive Staphylococcus epidermidis;
MRSE, methicillin-resistant Staphylococcus epidermidis; sp, species; IV, intravenous.
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Figure 4.4. Kaplan-Meier 5-year infection-free survival for the 1 versus 2 UPC cohorts.
Vertical spikes are censored data. UPC, unexpected positive intraoperative culture.

Detailed data for patients that had antibiotic treatment of their UPC(s) versus those that
did not have antibiotic treatment of their UPC(s) is shown in Table 4.5. The vast majority of
variables showed no statistical differences between cohorts (p >0.05), however important
differences were noted (Table 4.5). The antibiotic treatment cohort had a higher proportion of 2
UPCs (33.3% versus 10.2%, p =0.027). The increased proportions of worse American Society of
Anesthesiologists classification (p =0.078), UPCs from swab samples (p =0.064), and antibiotic
resistant microorganisms (p =0.125) in the antibiotic treatment cohort were not statistically
significant, nor were differences in UPCs from tissue samples (p =0.094) or microorganisms (p
=0.100). All 3 subsequent PJIs were in the antibiotic treatment cohort (p =0.042) and the 5-year
infection-free survival was worse for the antibiotic treatment cohort compared to the no
antibiotic treatment cohort, at 87.4% (95% CI 80.5% to 94.3%) and 100%, respectively (p
=0.021) (Figure 4.5). However, no patient with a single UPC without antibiotic treatment had a
subsequent PJI-related implant failure. Of note, there were no recurrent infections in patients
with 2 UPCs, but the majority received antibiotic treatment and numbers were low.
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Table 4.5. Baseline, demographic, operative, microbiological, treatment, and outcome data
for UPC revisions treated with antibiotics versus those not treated with antibiotics
Variable

Age (years)*
Sex, F/M, n (%)
BMI (kg/m2)†
ASA classification, n (%)
1
2
3
4
Diabetes, n (%)
Inflammatory condition, n (%)
Etiology for primary TKA, n (%)
Osteoarthritis
Other
Reasons for revision, n (%)
Aseptic loosening
Instability
Arthrofibrosis
Polyethylene wear +/- osteolysis
Patellar problem
Pain no known source
Periprosthetic fracture
Pain component malposition
History of prior TKA revision in study joint
n (%)
Age of prosthesis (years)†
History of PJI in study joint, n (%)
Pre-operative serum CRP > 10mg/L, n (%)
Pre-operative serum ESR > 30mm/h, n (%)
Preoperative joint aspirate, n (%)
Type of revision, n (%)
Patella
Modular exchange
1-component
2-component
Number of samples taken in study
revision†
1 UPC vs 2 UPC, n (%)
1 UPC
2 UPC
UPC from swab sample, n (%)
UPC from fluid sample, n (%)
UPC from tissue sample, n (%)
UPC broth or solid, n (%)
Broth
Solid
Microorganisms, n (%)

Antibiotic treatment

No antibiotic

(n = 27)

treatment (n =49)

69.6 (9.9)
19/8 (70.4/29.6)
34.2 (29.3 to 39.5)

69.1 (8.5)
28/21 (57.1/42.9)
32.8 (27.9 to 37.7)

0 (0)
4 (14.8)
21 (77.8)
2 (7.4)
6 (22.2)
4 (14.8)

0 (0)
14 (28.6)
35 (71.4)
0 (0)
12 (24.5)
6 (12.2)

23 (85.2)
4 (14.8)

43 (87.8)
6 (11.2)

14 (51.9)
7 (25.9)
1 (3.7)
3 (11.1)
1 (3.7)
1 (3.7)
0
0
3 (11.1)

20 (40.8)
15 (30.6)
5 (10.2)
1 (2.0)
3 (6.1)
3 (6.1)
1 (2.0)
1 (2.0)
8 (16.3)

10.9 (4.0 to 17.0)
1 (3.7)
4 (14.8)
2 (7.4)
8 (29.6)

8.6 (2.9 to 13.4)
1 (2.0)
5 (10.2)
5 (10.2)
16 (32.7)

2 (7.4)
2 (7.4)
4 (14.8)
19 (70.4)
4 (3.0 to 5.0)

2 (4.1)
6 (12.2)
4 (8.2)
37 (75.5)
4 (3.0 to 5.0)

P value

0.808a
0.256b
0.259c
0.078d

0.824b
0.737d
0.737d

0.684d

0.737d
0.373c
1.000d
0.714d
1.000d
0.786b
0.690d

0.485c
0.027d

18 (66.7)
9 (33.3)
22 (56.4)
0 (0)
17 (43.6)

44 (89.8)
5 (10.2)
20 (37.0)
1 (1.9)
33 (61.1)

18 (46.2)
21 (53.8)

30 (55.6)
24 (44.4)

0.064b
1.000d
0.094b
0.371b

0.100d
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C. acnes
Other CNS
MSSE
MRSE
Streptococcus sp
Enterococcus sp
Others
Number of revisions resistant UPC, n (%)
Subsequent aseptic revision, n (%)‡
Subsequent PJI, n (%)
Subsequent PJI microorganism, n (%)
Same as UPC microorganism
Mixed
Different than UPC microorganism

11 (24.4)
11 (24.4)
14 (31.1)
1 (2.2)
2 (4.4)
3 (6.7)
3 (6.7)
3 (11.0)
2 (7.4)
3 (11.1)

22 (38.6)
12 (21.1)
8 (14.0)
0 (0)
6 (10.5)
1 (1.8)
8 (14.0)
1 (2.0)
2 (4.1)
0 (0)

0 (0)
1 (33.3)
2 (66.7)

Not applicable
Not applicable
Not applicable

0.125d
0.612d
0.042d
Not applicable

*Values are mean (standard deviation). †Values are median (interquartile ranges). ‡Subsequent aseptic
revision after the study revision, censored out of survival analysis once occurs as subsequent PJI could be
caused by subsequent aseptic revision. aTwo-sample t test. bPearson’s chi-squared test. cMann-Whitney U.
d
Fisher’s exact test. UPC, unexpected positive intraoperative culture; F, female; M, male; BMI, body mass
index; ASA, American society of anesthesiologists; TKA, total knee arthroplasty; PJI, periprosthetic joint
infection; CRP, c-reactive protein; ESR, erythrocyte sedimentation rate; C. acnes, Cutibacterium acnes;
CNS, coagulase-negative Staphylococcus species; MSSE, methicillin-sensitive Staphylococcus epidermidis;
MRSE, methicillin-resistant Staphylococcus epidermidis; sp, species.

Figure 4.5. Kaplan-Meier 5-year infection-free survival for the UPC cohort treated with
antibiotics (yes) versus not treated with antibiotics (no).
Vertical spikes are censored data. UPC, unexpected positive intraoperative culture.
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4.4 Discussion
Literature on the prevalence, clinical significance, and outcomes of UPC in presumed
aseptic revision TKA is limited, with no clear consensus. Our aims were to determine the
prevalence of UPC in presumed aseptic revision TKA and the infection-free implant survival for
this patient population, as well as other clinical cohorts of interest. To our knowledge, this study
represents the largest series of UPC in presumed aseptic revision TKA in the literature.
The prevalence of UPC in presumed aseptic revision TKA in our study was 9.8%. This is
consistent with the mean prevalence of 10.5% (379/3605) for revision total hip (THA) and TKA
reported in literature, however the variability is substantial (4-38%), only 111 TKA with UPC
were included, and UPC in THA was twice more common than TKA(21). The variability in the
literature is due to significant heterogeneity between studies, including differing preoperative
evaluation and definitions of UPC or PJI(21). We included broth only UPCs since the specificity
of these cultures have been shown to be high(23), and other studies have as well(17–19). Studies
that included a single UPC as opposed to only 2 UPCs tended to report a higher
incidence(19,24–26), however, this is not universal(17), and those reporting on 2 UPC vary as
well(21). Barrack et al.(17) reported a prevalence of UPC in presumed aseptic revision TKA of
5.9% with 29/41 having a single UPC, Saleh et al.(19) reported a combined prevalence of 10%
for TKA and THA including those with a single UPC, and recently Jacobs et al.(18) reported a
prevalence of 7.9% in TKA patients when only considering 2 UPC as significant. In our
institution the prevalence of 2 UPC was only 1.8%. CNS species and C. acnes were the most
common microorganisms, supporting the indolent nature of microorganisms in UPC(17–19).
Virulent microorganisms did occur but were rare, as were antibiotic resistant
microorganisms(19,21).
The 2- and 5-year infection-free survival for the entire UPC cohort was excellent at
97.4% (95% CI 95.6% to 99.2%) and 95.3% (92.6% to 98.0%), respectively. The majority of
studies reporting similar infection-free survival in TKA and THA tended to be limited by short
follow-up or use advanced techniques such as implant sonication or molecular
techniques(14,26,29,30), both of which do not apply to the current study. The causative
microorganism in 2/3 of the subsequent PJIs was different than the UPC and the 5-year
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infection-free survival from a subsequent infection caused by the same UPC microorganism was
outstanding at 98.7% (95% CI 97.4% to 100%). Although subsequent PJI caused by different
microorganisms than the UPC likely represent a new infection, it is plausible that these
microorganisms were present during the study revision but missed due to the limited sensitivity
of cultures in PJI(27). A high proportion of subsequent PJI-related implant failure being caused
by a different microorganism than the UPC is common, however factors associated with
reinfection by the same microorganism have been identified(14,18,19,21). While most studies do
not report on TKA and THA separately, we felt this was important because Jacobs et al.(18)
showed that the prognosis for TKA is poorer than that of THA in this patient population.
Additionally, we felt that reporting out to 5-years was important given the low virulence
microorganisms common to UPC. The excellent infection-free survival of our large cohort was
consistent with the majority of literature(18,19,21,25,26,28), however, only 2 studies report the
survival of TKA separate from that of THA(17,18). Barrack et al.(17) reported at a mean of 45
months that only 2/41 of presumed aseptic TKA revisions with UPC went onto subsequent PJI.
However, Jacobs et al.(18) reported a 2-year survival of 88% (95% CI 60 to 97) in 17 TKA with
2 UPC, which was lower than that of the true aseptic TKA cohort.
We found that the infection-free survival was similar for the 1 UPC versus 2 UPC
cohorts. This was surprising and must be interpreted with caution due to important differences
between cohorts (proportion treated with antibiotics and the type of microorganisms involved).
Additionally, all of the subsequent infections were in the 1 UPC cohort, which is contrary to
most literature(17,21), but not all prior research(19). Possible explanations for this in our study
include differences in the proportion treated with antibiotics and causative microorganisms, the
high proportion of 2-component revisions, the low sample size of the 2 UPC cohort
(underpowered for comparisons), or other differences between cohorts not accounted for due to
the retrospective nature of the study.
Treatment protocols have varied considerably in the literature(17,21,28). In our study
only 35.5% (27) of patients received antibiotic treatment for their UPC(s). Of these, 92.6% (25)
were treated for a duration of ≤6 weeks and no patient is on life-long suppression. Surprisingly,
the infection-free survival was worse for the antibiotic treatment cohort. Similar results have
been reported(14,28), however, one cannot conclude antibiotic treatment is associated with a
higher risk of subsequent PJI based on our data. Differences between cohorts, lack of a
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standardized UPC treatment protocol, and the retrospective nature of our study introduced a
selection bias for those treated with antibiotics. Patients treated with antibiotics likely shared a
higher degree of clinical of suspicion for PJI or other factors that influenced clinicians to treat
medically.
There is debate regarding the clinical significance of a single UPC. Several studies
excluded revisions with only a single UPC(18,21,28), and others have questioned their
significance(17,21,25). No patient in our study with a single UPC deemed not to require
antibiotic treatment had a subsequent PJI-related implant failure. These results suggest that a
single UPC without signs of infection is likely a contaminant and does not require antibiotic
treatment, and support the conclusions of Barrack et al(17). We are unable to draw any
meaningful conclusions on antibiotic treatment and the significance of all 2 UPC in presumed
aseptic revisions, however it has been shown that even a single UPC with a high virulence
microorganism in a patient not meeting MSIS criteria may represent an infection and require
antibiotic treatment(19).
Our study has several limitations. The lack of a standardized treatment protocol for UPCs
and the retrospective design of this study is subject to associated biases, some of which are
discussed above. The academic, high-volume, single center design may limit external validity of
our results. However, our study included multiple surgeons at different points in their careers
potentially improving the generalizability of our results and most of our results are consistent
with the literature. Although it has been routine practice to order CRP and ESR for all failed
revisions, there was no standardized preoperative protocol to screen for PJI. An aspirate was only
ordered selectively, thus MSIS criteria could not be retrospectively applied. The type and
number of samples taken during revision surgery for culture was not standardized, and although
this is not uncommon to the UPC literature, both of have been shown to be important for
detecting microorganisms and PJI(24,31,32). Lastly, our study was underpowered to detect
differences between cohorts for secondary outcomes of interest and the low number of
subsequent PJI limited comparisons between cohorts. However, this study is the largest series of
UPC in presumed aseptic revision TKA in the literature, does not confound TKA results with
those of THA, and inclusion of revisions with a single UPC provides data on a common and
clinically relevant challenge for clinicians.
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In conclusion, the prevalence of UPC in presumed aseptic revision TKA is 9.8% and the
2- and 5-year infection-free survival is excellent. Infection-free survival when only considering
subsequent PJI caused by the same UPC microorganism is outstanding. The majority of
subsequent PJI-related failures were caused by a different microorganism than that of the UPC.
Infection-related survival was similar between the 1 and 2 UPC cohorts and the cohort treated
with antibiotics had an inferior survival compared to those not treated with antibiotics, however,
these findings must be interpreted with caution due to selection biases, differences between
cohorts, and sample size limitations. No patient in our study with a single UPC deemed not to
require antibiotic treatment had a subsequent PJI-related implant failure, strongly suggesting that
a single UPC without signs of infection is likely a contaminant and does not require antibiotic
treatment.
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Chapter 5

5.

Do Microorganisms Have a Role in ‘Aseptic’ Total Hip and

Knee arthroplasty Implant Failure? A Prospective Molecular Pilot
Study

5.1 Postponement of Study Completion Due to the COVID-19
Pandemic and State of Emergency
Due to the unprecedented current situation, this study is presented in its preliminary
format. The current state of emergency and Western University policies during the COVID-19
pandemic resulted in research laboratories being closed. Therefore, DNA extraction, PCR
amplification, sample processing and sequencing has been postponed for an unknown period of
time. However, all samples for molecular analysis have been collected and are safely stored. This
study will be completed at a future date, but when this will occur is uncertain and out of our
control. Thus, the introduction, methods, and preliminary results are presented in this chapter.
The current progress of the study is outlined in the methods section. Chapter 6 will include
discussion and future directions regarding this prospective of the thesis dissertation.

5.2 Introduction
Osteoarthritis is a leading cause of disability associated with significant patient suffering
and economic cost(1–3). Total hip (THA) and knee arthroplasty (TKA) are cost effective and
highly successful treatments for end-stage arthritis of the hip and knee(4,5). Over 1.5 million
THA and TKA are performed annually in North America(6,7), and the demand is increasing
greatly(7,8). Prosthetic implants can fail for a variety of reasons and require revision surgery to
treat. As approximately 12% of primary THA and TKA require revision surgery by the 10-year
mark(9), the number of revision surgeries will also increase substantially(7,8). Aseptic loosening
and periprosthetic joint infection (PJI) are among the leading causes for both early and late
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revision(6,10,11). PJI is a dreaded complication associated with substantial patient morbidity and
economic cost(12–16). Unfortunately, the burden of PJI will likely continue to increase because
the incidence has not decreased over time(16,17).
Several authors have questioned whether a proportion of ‘aseptic’ failures are actually
undiagnosed PJI-related failure(18–21). Despite tremendous scientific effort, there remains no
perfect test to diagnose PJI(22–24). Although identification of a causative microorganism
remains the gold standard in the diagnosis of PJI, 20-40% of confirmed PJI remains culturenegative due to sensitivity limitations of standard culture methods(25,26). Additionally,
unexpected positive intraoperative cultures (UPC) occur in approximately 10% of presumed
aseptic revisions and molecular methods have identified bacterial microorganisms on implants of
‘aseptic’ failures (27–32).
Thus, there has been increased interest in culture-independent molecular methods that
have several advantages over traditional cultures(33–35). The majority of these polymerase chain
reaction (PCR) based molecular studies have focused on the diagnosis of PJI, with suboptimal
results and an unclear role(33,34). Fewer molecular studies have evaluated the detection of
microorganisms in ‘aseptic’ failures and results have been conflicting(29–32,35–40). Several
authors question the significance of PCR based detection of microorganisms and others do not
support detection of true positive microorganisms or undiagnosed PJI in presumed aseptic
revisions, particularly those with a focus on the stringent control of contamination(35,37–
39,41,42).
The prevalence, role, and clinical significance of microorganisms identified in presumed
aseptic revisions using molecular techniques remains unclear. No molecular study has
investigated if there are specific areas on prosthetic implants that microorganisms are more likely
to be found and there have been conflicting results between studies using universal 16S
ribosomal RNA (16S rRNA) PCR primers versus multiplex genus/microorganism specific
primers(33,35,38,40–42). Therefore, we designed a prospective pilot study using modern
molecular techniques, a stringent control of contamination, and several samples from
predetermined sites of THA and TKA implants revised for presumed aseptic failure.
Using modern molecular and sequencing methods with an emphasis on the stringent
control of contamination our aims were to: (I) determine the frequency and type of bacterial
microorganisms on prosthetic implants from presumed aseptic THA and TKA failures, and
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compare the microorganisms identified by molecular methods to those of standard cultures, (II)
determine the type of implants and location on the implants that bacterial microorganisms are
found, and (III) determine if the presence of bacterial microorganisms is associated with the
reason for revision. We hypothesize that these implants will frequently be colonized by bacterial
microorganisms, molecular techniques will identify more microorganisms versus standard
intraoperative cultures, and that the presence of microorganisms will be associated with the
implant type, location, and reason for revision.

5.3 Methods
5.3.1

Participants and Sample Collection
This prospective pilot study received ethical approval by the Western University Health

Science Research Ethics Board (REB No 114030) and was funded in part by a Schulich
Collaborative Seed Research grant. All participants provided written informed consent prior to
inclusion in the study. Adult patients undergoing aseptic single-stage THA and TKA revision
surgery at a single high-volume, tertiary, academic center (University Hospital – London Health
Sciences Center) who provided informed consent were eligible for inclusion. Over an 8-month
time period (August 2019 to March 2020) a total of 41 patients (20 THA and 21 TKA) were
recruited for inclusion in this study. Revision surgeries were performed by one of seven
fellowship trained subspecialty arthroplasty surgeons. The sample size of this pilot study was one
of convenience (and funding) that will facilitate proper sample size power calculations for future
grant proposals and larger studies. Exclusion criteria were (I) unable or unwilling to give
consent, (II) known or suspected PJI, (III) on antibiotic suppression of a previous PJI, (IV) the
second of a 2-stage revision for PJI, and (V) no prosthetic components removed. Preoperatively
all patients were screened for PJI clinically and with serum erythrocyte sedimentation rate (ESR)
and c-reactive protein (CRP). A joint fluid synovial aspiration was performed only if clinical
history and preoperative serum markers did not rule out PJI. The Musculoskeletal Infection
Society definition of PJI was used to rule out infection when an aspiration was performed(23).
Although it was preferable that all patients had revision of a metallic prosthetic component
(acetabular cup or femoral stem for THA and femoral or tibial prosthesis in TKA), those that
underwent modular exchange only were not excluded from the study.
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Prior to skin incision all patients received routine weight-adjusted preoperative antibiotics
(cefazolin unless allergic) and skin preparation (2% chlorhexidine-70% isopropyl alcohol or
iodine-based) for postsurgical infection prophylaxis. All surgeries and sample collections were
performed in operating rooms with vertical laminar flow. A minimum of 3 deep intraoperative
samples for routine extended aerobic and anaerobic surgical cultures were performed, with a
preference for tissue. All cultures were monitored, and the microbiologic details of any positive
cultures documented. Routine sterile surgical technique was adhered to and surgeons were
careful to only handle only the minimum portion of the implants required to remove during
revision surgery. A member of the research team was present at each revision surgery for implant
sample collection for molecular analysis. Once explanted the implants were placed directly onto
a sterile tray by the surgeon to minimize the potential for contamination. Using sterile technique,
new individual sterile scalpel blades were used to scrape predetermined areas of the implants
(Appendix D). These sites were chosen to represent likely areas of biofilm formation on the
implants that were unlikely to be touched by the surgeon during extraction. There were 3
sampling sites for each standard metallic implant, as well as additional sites for modular
components (head and liner) (Appendix D). For revision or complex implants, all standard sites
were sampled when able and additional sites sampled were documented. Individual sterile swabs
were used for sampling on sites not amenable to scraping. Each scraping sample was placed in
individual sterile prelabelled Eppendorf tubes for storage and transport. Swab samples were
placed back into their individual sterile tubes. A separate sterile Eppendorf tube was left open to
air during the revision procedures to serve as an aerosol control. All implant samples and aerosol
controls were sealed, immediately deidentified for protection of patient privacy, stored at -20 °C
until DNA extraction, and transported to the Canadian Centre for Human Microbiome and
Probiotics at St. Joseph’s Health Care, London, ON. Baseline patient, demographic,
preoperative, operative, and microbiologic data of interest were collected for further analysis.
Currently, all implant samples are collected and stored at -20 °C at the Canadian Centre
for Human Microbiome and Probiotics at St. Joseph’s Health Care, London, ON. For the
molecular methodology described below it is important that all samples be prepared, processed
and sequenced at the same time. We were ready to proceed with DNA extraction, PCR
amplification, and sequencing, however, were postponed due to unforeseen and uncontrollable
circumstances. Unfortunately, due to the COVID-19 state of emergency and Lawson Health
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Research Institute policies during this pandemic, research laboratories have been closed and
further molecular preparation and analysis has been postponed. I have described the planned
molecular methodology below.

5.3.2

DNA Extraction, PCR Amplification, Sequencing, and

Data Analysis
Total DNA extraction (microbial and human) will be performed for each implant sample
in a biological safety cabinet using sterile tools pre-treated with RNase AWAY™ Surface
Decontaminant solution (Thermo Fisher Scientific Inc, Waltham, MA), as described in a
previous a previous publication(43). DNA from all samples (including aerosol controls) will be
extracted using the DNeasy PowerSoil HTP 96 Kit® (Qiagen, Germantown, MD). DNA blank
controls, containing only reagents used for DNA extraction, will be included in order to detect
any microbial contamination from the DNA isolation kits or reagents used in subsequent
procedures. Additionally, gram-negative, gram-positive, and PCR blank controls will be used.
DNA samples will be stored at - 20 °C until PCR amplification. A detailed protocol of the DNA
extraction is available at https://www.qiagen.com/gb/resources/resourcedetail?id=fd3fa52e-3a664d55-a9cd-7ed20ea046d9&lang=en.
A BioMek®3000 Laboratory Automation Workstation will be used to maximize the
accuracy and precision of the following PCR amplification procedures. DNA samples will be
aseptically transferred to 96-well plates containing forward and reverse PCR primers. Two types
of PCR primers will be used. The first will be a “universal” or “broad-range” PCR primer that
targets and amplifies the V4 hypervariable region of the bacterial 16S rRNA gene. This highly
preserved gene is universal and specific to bacterial microorganisms. These primers are all
different because they contain individual bar codes incorporated into the sequence. Thirty-two
primers (16 left and 16 right) with unique barcodes into 96 will be used. Amplifications of the
V4 region of the 16S ribosomal RNA gene will be carried out with the primers (5′-3′)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNxxxxxxxxGTGCCAGCMGCCGC
GGTAA and (5′-3′)
CGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCTNNNNxxxxxxxxGGACTACHVG
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GGTWTCTAAT (xxxxxxxx is a sample specific nucleotide barcode and the preceding sequence
is a portion of the Illumina adapter sequence for library construction).
However, it has been identified that universal 16S rRNA PCR primers have only moderate
sensitivity for coagulase-negative Staphylococcus (CNS) species and very poor sensitivity to
detect anerobic bacteria such as Cutibacterium acnes (C. acnes)(35). This is problematic because
C. acnes and CNS species were the most common microorganisms identified from UPC in
presumed aseptic revision THA and TKA at our institution (Chapter 3 and Chapter 4). Therefore,
we will also be using genus or group specific primers that target and amplify genes specific to C.
acnes and CNS species. This combined approach will allow us to detect rare or unexpected
microorganisms and maintain the ability to detect expected microorganisms with a high
sensitivity. The Illumina adapter sequences and unique barcode sequences appended to the 5’
end of the primers will allow us to unmistakably identify each sample.
A detailed protocol for preparation of the plates for gene sequencing can be found in
Appendix E. Prior to sequencing, the amplified DNA samples will be quantified using a QuantiT™ PicoGreen® dsDNA Assay Kit (Invitrogen), pooled at equimolar concentrations and
cleaned using the QIAquick PCR Purification Kit (Qiagen, Germantown, MD). An Illumina
MiSeq (2x220 cycles) will be used to sequence the purified samples at the London Regional
Genomics Centre, Robarts Research Institute and the output data processed at the Canadian
Centre for Human Microbiome and Probiotics, Lawson Health Research Institute. A PANDAseq
analysis tool will be used to remove the unpaired or low-quality reads, and the remaining highquality reads will be collated into “operational taxonomic units” (OTUs) based on 97% or greater
sequence identity. Putative taxonomies will be assigned by comparing the OTUs to the
Ribosomal Database Project (RDP) (http://rdp.cme.msu.edu/).
Only UTOs assigned to various families, genera, or species of microbiota will be
included, excluding all those assigned to human, other eukaryotic, mitochondrial, chloroplast, or
unclassified sequences. OTUs that implant samples and controls (blank DNA extraction controls
and surgical aerosol controls) have in common will be considered contamination and excluded.
Furthermore, to minimize the likelihood of false-positive findings, OTUs that were less than 1%
of the total number of reads in each sample will be excluded.
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5.3.3

Statistical Analysis
Statistical analysis of OTUs will be performed using R software as previously described

(43). Counts and proportions, medians and interquartile ranges (IQR) or means and standard
deviations (SD) will be used to report on outcomes of interest when appropriate. The frequency
of positive molecular microorganism identification on implants and the frequency of different
types of microorganisms will be determined. The frequency of UPC from standard intraoperative
cultures will be determined and these results compared to molecular findings. Microorganism
identification will be compared between those with and without UPC. The frequency of
microorganism identification on different types of implants and different locations on the
implants will be determined. We will compare these frequencies between reasons for revision
using an ANOVA (parametric) or Kruskal-Wallis (nonparametric) test depending on the
normality of the data and sample size. Categorical data will be compared using the Pearson’s chisquared test or Fisher’s exact test, when appropriate. Continuous data between two independent
cohorts will be compared using two-sample t tests or Mann-Whitney U tests for parametric and
nonparametric data, respectively. The Shapiro–Wilk test was used to test normality. Statistical
significance was 2-tailed and set at a p-value ≤0.05.

5.4 Preliminary Results
Baseline and preoperative variables for all 41 presumed aseptic revisions are shown in
Table 5.1. The entire cohort had a median age of 70.0 years (IQR 63.0 to 74.0) and BMI of 30.1
(27.0 to 35.8). Fifty-six percent (23) of the patients were female and the dominant reasons for
revision were aseptic loosening (39.0%) and instability (19.5%). Nearly one-third of patients had
a prior revision in the study joint. One patient (TKA) patient had a history of an acute
postoperative methicillin-sensitive Staphylococcus aureus PJI in the study joint successfully
treated with debridement, modular exchange, antibiotics and implant retention 4 years prior
(Table 5.1). This same patient later underwent subsequent aseptic revisions for aseptic loosening
and arthrofibrosis, but preoperative infection workup and intraoperative cultures in our study
were negative. Roughly one-tenth of patients had an elevated CRP (9.8%) and ESR (12.2%), and
24.4% (10) underwent a preoperative joint fluid aspiration to rule out PJI. There was some
variability between THA and TKA cohorts in variables examined (Table 5.1).
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Table 5.1. Baseline and preoperative data for all patients and by joint type
Variable

Total (n = 41)

THA (n = 20)

TKA (n = 21)

Age (years)*
Sex, n (%)
Female
Male
BMI (kg/m2)*
ASA, n (%)
2
3
Inflammatory condition, n (%)
Etiology for primary, n (%)
Osteoarthritis
Avascular necrosis
Neck of femur fracture
Dysplasia
Perthes
Reasons for revision, n (%)
Aseptic loosening
Instability
Arthrofibrosis
Polyethylene wear +/- osteolysis
Adverse metal reaction
Metal allergy
Implant fracture
Pain/mechanical symptoms
Chronic patella dislocation
Prior revision in study joint, n (%)
History of PJI in study Joint, n (%)
Preoperative serum CRP  10mg/L, n (%)
Preoperative serum ESR  30mm/h. n (%)
Preoperative joint aspirate, n (%)

70.0 (63.0 to 74.0)

66.5 (61.5 to 76.75)

71.0 (66.0 to 74.0)

23 (56.1)
18 (43.9)
30.1 (27.0 to 35.8)

11 (55.0)
9 (45.0)
28.3 (26.2 to 30.1)

12 (57.1)
9 (42.9)
35.8 (29.7 to 40.7)

8 (19.5)
33 (80.5)
1 (2.4)

5 (25.0)
15 (75.0)
1 (5.0)

3 (14.3)
18 (85.7)
0 (0)

35 (85.4)
3 (7.3)
1 (2.4)
1 (2.4)
1 (2.4)

15 (75.0)
2 (10.0)
1 (5.0)
1 (5.0)
1 (5.0)

20 (95.2)
1 (4.8)
n/a
n/a
n/a

16 (39.0)
8 (19.5)
5 (12.2)
4 (9.8)
4 (9.8)
1 (2.4)
1 (2.4)
1 (2.4)
1 (2.4)
13 (31.7)
1 (2.44)
4 (9.8)
5 (12.2)
10 (24.4)

8 (40.0)
3 (15.0)
0 (0)
3 (15.0)
4 (20.0)
0 (0)
1 (5.0)
1 (5.0)
n/a
4 (20.0)
0 (0)
3 (15.0)
3 (15.0)
5 (25.0)

8 (38.1)
5 (23.8)
5 (23.8)
1 (4.8)
0 (0)
1 (4.8)
0 (0)
0 (0)
1 (4.8)
9 (42.9)
1(4.8)
1 (4.8)
2 (9.5)
5 (23.8)

*Values are median (interquartile ranges). THA, total hip arthroplasty; TKA, total knee arthroplasty; BMI,
body mass index; ASA, American society of Anesthesiologists classification; PJI, periprosthetic joint
infection; CRP, c-reactive protein; ESR, erythrocyte sedimentation rate.

Two-component exchange was the most common type of revision (41.5%), followed by
1-component exchange (34.1%), and modular exchange only (24.4%) (Table 5.2). In the THA
cohort 1-component exchange (55.0%) was the most common type of revision performed
followed by modular exchange (30.0%), and for TKA it was 2-component exchange (66.7%)
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followed by modular exchange (19.0%) (Table 5.2). A median of 4 (IQR 4 to 5) intraoperative
surgical samples for standard cultures were taken per revision and a majority of these samples
were tissue (80.6%) (Table 5.2).
Table 5.2. Type of surgery and standard laboratory culture data for all patients and by
joint type
Variable
Type of revision, n (%)
Modular exchange
1-component
2-component
Total number of intraoperative samples
taken for standard culture*
Swab samples, n (%)
Fluid samples, n (%)
Tissue samples, n (%)
Number of intraoperative samples taken
per revision for standard culture†

Total (n = 41)

THA (n = 20)

TKA (n = 21)

10 (24.4)
14 (34.1)
17 (41.5)
186

6 (30.0)
11 (55.0)‡
3 (15.0)
83

4 (19.0)
3 (14.3)‡
14 (66.7)
103

19 (10.2)
17 (9.1)
150 (80.6)
4 (4 to 5)

13 (15.7)
4 (4.8)
66 (79.5)
4 (3.75 to 5)

6 (5.8)
13 (12.6)
84 (81.6)
4 (4 to 5)

*All intraoperative samples taken were send for aerobic, anerobic, and extended (14 days) cultures in the
hospital laboratory. †Values are median (interquartile ranges). ‡In the 1-component exchanges there were
6 acetabulum & 5 femurs for THA and 1 femur & 2 tibias for TKA. THA, total hip arthroplasty; TKA, total
knee arthroplasty.

The prevalence of UPC was 9.8% (4/41) for the entire cohort, 10.0% (2/20) for THA and
9.5% (2/21) for TKA. Details of the 4 patients with UPC can be seen in Table 5.3. Only 1 patient
had a history of a prior revision in the study joint and no patients had a history of PJI.
Preoperative screening serum CRP and ESR were normal and no patient underwent a
preoperative joint aspirate. Each patient had a single UPC (one with 2 microorganisms) and all
microorganisms were isolated from broth only (Table 5.3). C. acnes was the most common
microorganism (3/4 patients), followed by Staphylococcus Epidermidis (1/4), and Anaerococcus
octavius (1/4) (Table 5.3).
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Table 5.3. Details of the 4 patients with unexpected positive intraoperative cultures
Variable
Joint type
Age (years)
Sex
BMI (kg/m2)
Etiology for primary
Reason for revision
Prior revision in study
joint
History of PJI in study
joint
Preoperative serum
CRP (mg/L)
Preoperative serum
ESR (mm/h)
Preoperative joint
aspirate
Type of revision
Number of samples
taken for standard
culture*
Number of UPCs
UPC solid or broth
UPC sample type
UPC microorganism(s)

Case 1

Case 2

Case 3

Case 4

THA
62
Male
26.0
Osteoarthritis
Aseptic
loosening
No

THA
26
Female
33
DDH
Instability

TKA
74
Female
40.7
Osteoarthritis
Aseptic loosening

TKA
66
Male
47.3
Osteoarthritis
Aseptic loosening

Yes (instability)

No

No

No

No

No

No

4.2

2.9

2.2

1.3

7

11

14

8

No

No

No

No

1-component
4

Modular
7

1-component
5

1-component
5

1
Broth
Tissue (aerobic)
Staphylococcus
Epidermidis

1
Broth
Swab (anaerobic)
Cutibacterium
acnes

1
Broth
Tissue (anaerobic)
Cutibacterium
acnes +
Anaerococcus
octavius

1
Broth
Tissue (anaerobic)
Cutibacterium
acnes

*All intraoperative samples taken were send for aerobic, anerobic, and extended (14 days) cultures in the
hospital laboratory. THA, total hip arthroplasty; TKA, total knee replacement; BMI, body mass index; DDH,
developmental dysplasia of the hip; PJI, periprosthetic joint infection; CRP, c-reactive protein; ESR,
erythrocyte sedimentation rate; UPC, unexpected positive intraoperative culture.

A total of 248 implant samples and 41 operative aerosol controls to be included in the
molecular analysis are currently being stored at the Canadian Centre for Human Microbiome and
Probiotics at St. Joseph’s Health Care, London, ON. Complete results are pending post COVID19 crisis.
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5.5 Discussion
Pending completed results.

5.6 Conclusions
Pending completed results.
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Chapter 6
6.

Conclusions

6.1 Unexpected Positive Intraoperative Cultures in Presumed
Aseptic Revision THA and TKA
This thesis represents the largest series of unexpected positive intraoperative cultures
(UPC) in presumed aseptic revision for both total hip (THA) and knee arthroplasty (TKA). Our
results are a valuable addition to the literature and can be used by clinicians to counsel patients
on expected outcomes and as an aid in decision making.

6.1.1

UPC in Presumed Aseptic Revision THA
We showed that the prevalence of UPC was 9.2% and that the 2- and 5-year infection-

free survival was encouraging (93.1% and 86.8%, respectively). Infection-free survival when
only considering infection-related implant failure by the same UPC microorganism is excellent
(95.8% and 94.3%). We did not find a difference in infection-free survival between cohorts of
interest (1 versus with 2 UPC and 1 UPC treated with antibiotics versus not treated with
antibiotics), but this must be interpreted with caution. Patients with 2 UPC and those with a
single UPC treated with antibiotics were more likely to have recurrent infection-related implant
failure caused by the same UPC microorganism (100% and 100%, respectively). Patients with a
single UPC are unlikely to have recurrent infection by the same UPC microorganism (25% in
antibiotic treatment versus 0% in the no antibiotic treatment cohorts). Finally, patients with a
single UPC and no other signs of infection can be considered contaminants, and do not require
antibiotic treatment. However, this may not be absolute or universal to all cases and host status,
reason for revision, microorganism, and surgical factors need to be considered when making
treatment decisions.
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6.1.2

UPC in Presumed Aseptic Revision TKA
Similarly, we demonstrated that the prevalence of UPC was 9.8% and the 2- and 5-year

infection free survival is excellent (97.4% and 95.3%, respectively). For TKA the infection-free
survival when considering only infection-related implant failure by the same UPC
microorganism is outstanding (98.7%). The majority of subsequent infection-related failures
were caused by a different microorganism than the UPC (66.7%). Infection-free survival was
similar for the 1 versus 2 UPC cohorts, however, it was poorer for the cohort treated with
antibiotics versus those not treated with antibiotics. Again, these comparisons between cohorts
must be interpreted with caution due to selection biases, differences between cohorts, and sample
size limitations. No patient with a single UPC that was deemed not to require antibiotic treatment
had a subsequent infection-related implant failure, strongly suggesting that a single UPC without
signs of infection is likely a contaminant and does not require antibiotic treatment. However, this
may not be absolute or universal to all cases and host status, reason for revision, microorganism,
and surgical factors need to be considered when making treatment decisions.

6.1.3

Limitations and Future Directions
The major limitations of these studies were the retrospective and single center design,

lack of a standardized UPC treatment protocol, absence of a standardized intraoperative
sampling protocol (type, number), and sample size limitations between cohorts for secondary
outcomes of interest. A selection bias existed for those deemed to require antibiotic treatment
and limited our ability to establish UPC treatment protocol recommendations.
Many authors have advised that prospective evaluation of UPC in presumed aseptic
revision THA and TKA is unlikely to occur because of the infrequent nature of the problem. It is
the current author’s opinion that this is wrong. We showed that the prevalence of UPC is
approximately 10% (consistent with the mean prevalence in the literature). The number of
revision cases will increase substantially and periprosthetic joint infection remains a devastating
complication with no perfect diagnostic test. Thus, a well-designed, multicenter, prospective
study on this subject matter is feasible and required to establish the clinical significance and
proper treatment protocols for UPC in presumed aseptic revision. Additionally, since there is not
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universal agreement that all revisions require intraoperative cultures (especially those with a low
index of suspicion for infection), there is a potential need for future cost-effectiveness analyses.

6.2 Do Microorganisms Have a Role in ‘Aseptic’ Total Hip and
Knee arthroplasty Implant Failure? A Prospective Molecular Pilot
Study
.
We hypothesized that these implants will frequently be colonized by bacterial
microorganisms, molecular techniques will identify more microorganisms versus standard
intraoperative cultures, and that the presence of microorganisms will be associated with the
implant type, location, and reason for revision. Our specific aims were to use modern molecular
and sequencing methods with an emphasis on the stringent control of contamination to, (I)
determine the frequency and type of bacterial microorganisms on prosthetic implants from
presumed aseptic THA and TKA failures, and compare the microorganisms identified by
molecular methods to those of standard cultures, (II) determine the type of implants and location
on the implants that bacterial microorganisms are found, and (III) determine if the presence of
bacterial microorganisms is associated with the reason for revision.
As previously described, all samples for molecular analysis are collected and safely
stored. However, due to the unprecedented COVID-19 pandemic and state of emergency, the
completion of the molecular portion of this study has been postponed.
The UPC microorganisms identified in our database studies were helpful to the molecular
methodology of this prospective pilot study and led to the utilization of both universal and
genus/species specific PCR primers. Additionally, the approximately 40/60 split for etiology for
revision (aseptic loosening versus other aseptic failure modes) will aid in the potential
identification of an association between molecular identification of microorganisms and reason
for revision.
Preliminary results from the prospective molecular study supports our work on the
prevalence of UPC (standard surgical cultures) in presumed aseptic revision THA and TKA. The
indolent nature of the microorganisms identified is also consistent with our previous work. The
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normal preoperative clinical history, serum C-reactive protein and erythrocyte sedimentation rate
values in patients with UPC shows how unpredictable these positive cultures can be.
No molecular study has investigated if there are specific areas on prosthetic implants that
microorganisms are more likely to be found. If these locations were to be discovered, this would
have important implications. The prevalence and role and of microorganisms identified in
presumed aseptic revisions using molecular techniques remains unclear, and the clinical
significance in terms of implant survival and functional outcomes is virtually unknown. Our pilot
study will not be able to answer these questions definitively, nor was it designed to. Data from
this pilot study will be used to perform appropriate power calculations, obtain funding, and
design large studies that can definitively determine the role and clinical implications of
microorganisms identified by modern molecular techniques in presumed aseptic revisions. If we
identify that ‘aseptic’ failures are frequently colonized with microorganisms, future molecular
studies should follow these patients longitudinally to evaluate the clinical significance of this.
The role of microorganisms in presumed aseptic revision THA and TKA may have been
underestimated and this clearly necessitates ongoing investigation.
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• Toronto, ON

2010 - present

Canadian Medical Association (CMA)

2010 - 2014

Ontario Medical Association (OMA)

ACADEMIC AWARDS & ACCOMPLISHMENTS
2019 (Accepted)

The Hip Society / M.E Müller Foundation of North America
European Fellowship
• Competitive application process for North American
trained Orthopaedic Surgeons; my application was
successful, and I awarded the funded fellowship for 2020
• Funding: $40,000 (USD)

2018

UBC Resident Research Day Competition – Second Prize
• Awarded to the resident with the second-best podium
presentation at the annual research day, Department of
Orthopaedics, University of British Columbia

2014 – 2018

Orthopaedic in-Training Examination (OITE)
• PGY-5 100th percentile all takers (Canadian & US)
• PGY-3 99th percentile
• PGY-2 97th percentile
• PGY-1 92cnd percentile

2016

“Blue Ribbon Article” – Selected by the Editors of
Orthopedics as a significant contribution to the literature
• Neufeld ME, O’Hara NN, Zhan M, Zhai Y, Broekhuyse
HM, Lefaivre KA, Abzug JM, Slobogean GP. Timing of
Hip Fracture Surgery and 30-Day Outcomes.
Orthopedics. 2016; 39(6):361-368.

2015

UBC Resident Research Day Competition – Second Prize
• Awarded to the resident with the second-best podium
presentation at the annual research day, Department of
Orthopaedics, University of British Columbia

2014

Dr. Kenzie Takahashi Scholarship in Medicine and Surgery
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•

Graduation scholarship awarded to the student with
highest academic standing in medicine and surgery
during clerkship in the graduating class, Faculty of
Medicine, University of Toronto

2014

Irving Heward Cameron Undergraduate Scholarship in
Surgery
• Graduation scholarship awarded to the students who
achieved the highest academic standing in Surgery
during clerkship in the graduating class, Faculty of
Medicine, University of Toronto

2013

Dr. F.J. Colling O.B.E. Memorial Scholarship
• In recognition of high academic standing in the third year
of medical school, Faculty of Medicine, University of
Toronto

2012

CREMS (Comprehensive Research Experience for Medical
Students) - Summer Program
• CIHR Scholarship Recipient - University of Toronto

2012

Dr. F.J. Colling O.B.E. Memorial Scholarship
• In recognition of high academic standing in the second
year of medical school, Faculty of Medicine, University
of Toronto

2008

CSEP (Canadian Society for Exercise Physiology)
Undergraduate Award - Brock University
• Presented by the CSEP each year to the student
graduating in that academic year in physical education,
human kinetics, or related disciplines with the highest
standing in the scientific portion of the curriculum in
their respective Canadian university.

2008

First Class Honours – BSc (Honours) in Kinesiology
• Brock University, St. Catharines, ON

2003 – 2008

Dean’s Honour List – BSc (Honours) in Kinesiology
• Brock University, St. Catharines, ON

2003 – 2008

Student Athlete Scholarship
• For CIS (Canadian Interuniversity Sport) and academic
achievement
• Brock University, St. Catharines, ON

2006

R.M. Davis Surgite Award

136

•
•

Awarded to the male varsity athlete that has the highest
academic grade point average and best combines
athletics and academics
Brock University, St. Catharines, ON

2003

Brock Scholars Award
• $14, 000 to the student that on admission to Brock
University has an admission grade point average of
93.0% and above
• Brock University, St. Catharines, ON

2003

Governor General’s Academic Medal
• Awarded to the student with the highest grade point
average in their graduating secondary school class
• Governor Simcoe Secondary School, St. Catharines, ON

GRANTS
1.

Canadian Institutes of Health Research (CIHR): Canada
Graduate Scholarships-Master’s (CGS M) Frederick Banting
and Charles Best Scholarship
• Competitive annual national CIHR scholarship
competition open to Canadian Master’s applicants, I was
awarded this based on the merit of my MSC in Surgery
project
• $17,500 (CAD)
• 2019

2.

Canadian Institutes of Health Research (CIHR)
• Awarded upon successful application to the University of
Toronto’s CREMS (Comprehensive Research Experience
for Medical Students) Summer Program to support the
study “The Impact of Socioeconomic Status on Implant
Selection for Patients Undergoing Hip Arthroplasty”
• $2750 (CAD)
• 2012

SCIENTIFIC PRESENTATIONS
2019

Can the Oxford Hip and Knee Score Identify Patients that
Don’t Require Total Knee or Hip Arthroplasty?
• Podium Presentation
• Canadian Orthopaedic Association (COA) Annual
Meeting, Montreal, ON
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2018

Can the Oxford Knee and Hip Scores Identify Patients that
Don’t Require Total Knee or Hip Arthroplasty?
• Podium presentation (presented by coauthor Dr. BA
Masri - closed meeting to Hip Society members)
• The Hip Society 2018 Summer Meeting, New York, NY,

2018

The Longitudinal Short, Medium, and Long-Term
Functional Recovery after Unstable Pelvic Ring Injuries
• Podium Presentation
• Canadian Orthopaedic Association (COA) Annual
Meeting, Victoria, BC

2018

Can the Oxford Hip and Knee Score Identify Patients that
Don’t Require Total Knee or Hip Arthroplasty?
• Podium Presentation
• UBC Department of Orthopaedics Annual Research Day,
Orthopaedic Update and BCOA Annual Meeting,
Vancouver, BC

2017

The Longitudinal Short, Medium, and Long-Term
Functional Recovery after Unstable Pelvic Ring Injuries
• Podium Presentation
• Orthopaedic Trauma Association (OTA) Annual
Meeting, Vancouver, BC

2017

A Comparison of Mobile and Fixed-Bearing
Unicompartmental Knee Arthroplasty at Minimum 10-Year
Follow-up
• Podium Presentation
• Canadian Orthopaedic Association (COA) Annual
Meeting, Ottawa, ON

2017

The Longitudinal Short, Medium, and Long-Term
Functional Recovery after Unstable Pelvic Ring Injuries
• Podium Presentation
• UBC Department of Orthopaedics Annual Research Day,
Orthopaedic Update and BCOA Annual Meeting,
Vancouver, BC

2016

Does the Surgical Treatment of Hip Fractures within TwoDays of Injury Improve Patient Outcomes? An Analysis of
26,066 Cases from ACS-NSQIP
• Podium Presentation (presented by coauthor Nathan
O’Hara)
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•

Canadian Orthopaedic Association (COA) Annual
Meeting, Quebec City, Quebec

2016

Survivorship and Outcomes of Unicompartmental Knee
Arthroplasty at Minimum 10-Year Follow-up
• Podium Presentation
• UBC Department of Orthopaedics Annual Research Day,
Orthopaedic Update and BCOA Annual Meeting,
Vancouver, BC

2015

US Hospitals Frequently Miss the British NICE Benchmark
for Time to Hip Fracture Surgery: Does it Matter?
• Podium Presentation
• Canadian Orthopaedic Residents Association (CORA)
Annual Meeting, Vancouver, BC

2015

US Hospitals Frequently Miss the British NICE Benchmark
for Time to Hip Fracture Surgery: Does it Matter?
• UBC Department of Orthopaedics Grand Rounds

2015

US Hospitals Frequently Miss the British NICE Benchmark
for Time to Hip Fracture Surgery: Does it Matter?
• Podium Presentation PGY-1
• UBC Department of Orthopaedics Annual Research Day,
Orthopaedic Update and BCOA Annual Meeting,
Vancouver, BC

2014

The Impact of Socioeconomic Status on Access to Care for
Patients Undergoing Hip Arthroplasty
• Poster Presentation
• American Academy of Orthopaedic Surgeons (AAOS)
Annual Meeting, New Orleans, Louisiana, USA

2013

The Impact of Socioeconomic Status on Access to Care for
Patients Undergoing Hip Arthroplasty
• Podium Presentation (presented by coauthor Dr. Michael
Olsen)
• Canadian Orthopaedic Association (COA) Annual
Meeting, Winnipeg, Manitoba

2013

The Impact of Socioeconomic Status on Access to Care for
Patients Undergoing Hip Arthroplasty
• Poster Presentation (presented by coauthor Dr. Emil
Schemitsch)
• Orthopaedic Research Society (ORS) Annual Meeting,
San Antonio, Texas, USA
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2013

The Impact of Socioeconomic Status on Access to Care for
Patients Undergoing Hip Arthroplasty
• Poster Presentation
• University of Toronto Medical Student Research Day,
Toronto, ON

2012

The Impact of Socioeconomic Status on Access to Care for
Patients Undergoing Hip Arthroplasty
• Podium Presentation (presented by coauthor Dr. Emil
Schemitsch – closed meeting to fellows and staff)
• Canadian Orthopaedic Arthroplasty Society (COAS)
Inaugural Meeting, London, ON

PUBLICATIONS
1.

(Accepted for publication) Garceau S, Igbokwe E, Warschawski Y,
Neufeld ME, Wade JP, Guy P, Safir O, Wolfstadt JI. Management
Options and Outcomes for Patients with Femur Fractures with
Post-Polio Syndrome of the Lower Extremity: A Critical Analysis
review. JBJS Reviews. Accepted for publication 23 April 2020.

2.

Neufeld ME, Broekhuyse HM, O’Brien PJ, Guy P, Lefaivre KA.
The Longitudinal Short, Medium, and Long-Term Functional
Recovery After Unstable Pelvic Ring Injuries. J Orthop Trauma.
2019 Dec;33(12):608-613.

3.

Neufeld ME & Masri BA. Can the Oxford Knee and Hip Score
Identify Patients that Don’t Require Total Knee or Hip
Arthroplasty? Bone Joint J. 2019 June;101-B(6_Supple_B):23-30.

4.

Neufeld ME, Albers A, Greidanus NV, Garbuz DS, Masri BA.
A Comparison of Mobile and Fixed-Bearing Unicompartmental
Knee Arthroplasty at Minimum 10-Year Follow-up. J Arthroplasty.
2018 Jun;33(6):1713-1718.

5.

Neufeld ME, O’Hara NN, Zhan M, Zhai Y, Broekhuyse HM,
Lefaivre KA, Abzug JM, Slobogean GP. Timing of Hip Fracture
Surgery and 30-Day Outcomes. Orthopedics. 2016; 39(6):361-368.

6.

Olsen M, Neufeld ME, Sellan M, Morison Z, Schemitsch EH. The
Impact of Socioeconomic Status on Implant Selection for Patients
Undergoing Hip Arthroplasty. UTMJ. 2015; 92(2):39-43.
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BOOK CHAPTERS
1.

Elserafi, J., Neufeld, M., Ravichandiran, K, and Stockton, D.
(Chapter Editors). Orthopedics. Toronto Notes 2014, 30th edition,
Type and Graphics.

